JNJ-7706621 vs. Cytochalasin B: A New Paradigm for Enhancing SCNT Embryo Development and Cloning Efficiency

Abstract

Somatic cell nuclear transfer (SCNT) is a pivotal technique for animal cloning and regenerative medicine, yet its efficiency remains low due to poor embryonic developmental competence. This article provides a comprehensive comparative analysis of two key chemical treatments: the novel cyclin-dependent kinase inhibitor JNJ-7706621 and the conventional cytoskeletal agent cytochalasin B. We explore their foundational mechanisms, methodological applications, and optimization strategies for SCNT embryo culture. Evidence demonstrates that JNJ-7706621 significantly outperforms cytochalasin B by enhancing cytoskeletal integrity, reducing DNA damage, and improving critical outcomes such as blastocyst formation, implantation rates, and live birth success. This review synthesizes current research to offer scientists and drug development professionals actionable insights for troubleshooting and validating SCNT protocols, ultimately advancing the field of reproductive biotechnology.

Understanding SCNT Challenges and the Role of Cytoskeletal Inhibitors

The Fundamental Hurdles in SCNT Embryo Development

Somatic cell nuclear transfer (SCNT) is a pivotal technique in reproductive biotechnology, yet its application is constrained by persistently low efficiency. A significant developmental bottleneck occurs after embryo activation, where the integrity of the cytoskeleton and proper chromosome segregation are paramount for successful preimplantation development. This guide compares two key chemical approaches—JNJ-7706621, a specific inhibitor of cyclin-dependent kinase 1 (CDK1) and aurora kinases, and the traditional agent cytochalasin B (CB), which primarily inhibits actin polymerization—in overcoming these critical hurdles. The supporting data, derived from recent studies, are summarized herein to provide a clear, objective comparison for research applications.

Experimental Comparison of JNJ-7706621 and Cytochalasin B

The following quantitative data, derived from controlled studies on mouse models, provide a direct comparison of the effects of post-activation treatment with JNJ-7706621 versus cytochalasin B on SCNT embryo development.

Table 1: Comparative Effects on Preimplantation Development in Mouse SCNT Embryos

Developmental Parameter	Cytochalasin B (CB)	JNJ-7706621 (JNJ, 10 μM)	Reference
Blastocyst Formation Rate	39.9% ± 6.4	61.4% ± 4.4	[1] [2]
Total Blastocyst Cell Number	52.7 ± 3.6	70.7 ± 2.9	[1] [2]
Inner Cell Mass (ICM) Cells	10.4 ± 0.7	15.4 ± 1.1	[1] [2]
Trophectoderm (TE) Cells	42.3 ± 3.3	55.3 ± 2.5	[1] [2]
Apoptotic Cell Index	Higher	Decreased	[1] [2]

Table 2: Comparative Effects on Post-Implantation Outcomes in Mouse SCNT Embryos

Developmental Parameter	Cytochalasin B (CB)	JNJ-7706621 (JNJ, 10 μM)	Reference
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	[1] [2]
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	[1] [2]

Detailed Experimental Protocols

To ensure reproducibility and provide context for the comparative data, the key methodologies from the cited studies are outlined below.

Protocol for Post-Activation Treatment in Mouse SCNT

This protocol is central to the comparative data presented in Tables 1 and 2 [1] [2].

• Oocyte Collection & SCNT: Perform standard SCNT procedures using enucleated mouse oocytes and somatic donor cells.
• Embryo Activation: After nuclear transfer, activate the reconstructed SCNT embryos to initiate development.
• Treatment Groups: Culture the activated embryos in one of the following conditions:
  • Control Group: 5 μg/mL cytochalasin B (CB).
  • Experimental Group: 10 μM JNJ-7706621 (a concentration determined as optimal from prior parthenogenetic activation assays).
• Treatment Duration: Expose embryos to the compounds for 4 hours post-activation.
• In Vitro Culture (IVC): After treatment, wash the embryos and culture them in standard embryo culture medium until blastocyst stage for analysis or embryo transfer to assess post-implantation development.

Underlying Mechanism Analysis

The superior performance of JNJ-7706621 is attributed to its targeted mechanism of action, which was investigated through the following analyses [1] [2]:

• Cytoskeletal Integrity: Immunofluorescence staining of F-actin and tubulin in one-cell embryos to assess the proportion of embryos with aberrant filamentous structures.
• Spindle & Chromosome Analysis: Immunostaining of spindles (α-tubulin) and DNA (DAPI) in one-cell embryos to quantify abnormal spindle morphology and chromosome misalignment.
• DNA Damage Assessment: Analysis of blastomere fragmentation and DNA damage markers (e.g., γH2AX) in two-cell SCNT embryos.

Mechanism of Action: Signaling Pathways

The fundamental difference between JNJ-7706621 and cytochalasin B lies in their molecular targets and subsequent impact on embryonic reprogramming. The following diagram illustrates the key pathways and mechanisms involved.

Mechanistic Pathways of JNJ-7706621 vs. Cytochalasin B

The Scientist's Toolkit: Key Research Reagent Solutions

The following table details essential reagents and their functions for researching post-activation treatments in SCNT embryo development, based on the featured comparison.

Table 3: Essential Research Reagents for SCNT Post-Activation Studies

Reagent	Category/Function	Key Application in SCNT Research
JNJ-7706621	CDK1 & Aurora Kinase Inhibitor	Post-activation treatment to improve cytoskeletal integrity, chromosome stability, and full-term development in mouse and porcine SCNT embryos. Typical working concentration: 10 μM. [1] [3]
Cytochalasin B (CB)	Actin Polymerization Inhibitor	A standard control agent for post-activation treatment, used to suppress polar body extrusion but associated with higher cytoskeletal abnormalities. Typical working concentration: 5 μg/mL. [1] [3]
Antibody: α-Tubulin	Immunofluorescence Staining	Visualizes microtubule and spindle structure in one-cell embryos to assess cytoskeletal normality. [1] [4]
Antibody: 5-methylcytosine (5mC)	Immunofluorescence Staining	Assesses global DNA methylation status, an indicator of epigenetic reprogramming efficiency. [5] [6]
DAPI Stain	Fluorescent DNA Labeling	Counterstaining for nuclei and chromosome visualization in conjunction with cytoskeletal and epigenetic markers. [1] [4]
H2DCFDA Assay	Reactive Oxygen Species (ROS) Detection	Measures intracellular ROS levels in embryos, a key marker of oxidative stress related to developmental arrest. [7] [6]
Dihydroartemisinin	Dihydroartemisinin	High-purity Dihydroartemisinin (CAS 71939-50-9), the active metabolite of Artemisinin. For research applications such as antimalarial mechanisms and drug discovery. RUO, not for human use.
Cabotegravir Sodium	Cabotegravir Sodium, CAS:1051375-13-3, MF:C19H16F2N3NaO5, MW:427.3 g/mol	Chemical Reagent

Key Research Insights

The comparative data reveals that JNJ-7706621 is not merely an alternative but a significant improvement over cytochalasin B for post-activation treatment in mouse SCNT. Its mechanism extends beyond the physical containment offered by CB to actively promote epigenetic reprogramming by reducing DNA damage and enhancing chromosomal stability [1]. This results in a more robust foundation for subsequent embryonic genome activation (EGA) and placental development, as evidenced by the marked increase in inner cell mass and trophectoderm cells [1] [2]. For researchers, this direct comparison underscores that targeting the regulatory kinases of the cell cycle (CDK1) and mitosis (Aurora kinases) post-activation is a more effective strategy than solely manipulating the actin cytoskeleton for achieving viable, full-term SCNT embryos.

Somatic Cell Nuclear Transfer (SCNT) requires precise manipulation of the oocyte's cytoskeleton to successfully reprogram a somatic nucleus into a totipotent state. For decades, cytochalasin B (CB) has served as the conventional workhorse in this critical process, primarily functioning to prevent the extrusion of a pseudo-polar body after artificial activation—a key step in maintaining diploidy in reconstructed embryos. This mechanistic action is achieved through CB's well-characterized inhibition of actin polymerization, which stabilizes the oocyte's structural integrity during the delicate nuclear transfer procedure. While CB has established a long history of reliable performance across multiple species, the evolving field of reproductive biotechnology has introduced alternative agents such as JNJ-7706621, a cyclin-dependent kinase inhibitor that offers a different mechanism of action. This comparison guide objectively evaluates the experimental performance of these two compounds, providing researchers with structured quantitative data and detailed methodologies to inform reagent selection for SCNT embryo development research.

Mechanism of Action: Distinct Pathways for Improving SCNT Outcomes

Cytochalasin B: The Actin-Disrupting Agent

Cytochalasin B operates through a well-defined mechanism that directly targets the oocyte's cytoskeletal architecture. As a cytochalasan, CB specifically binds to the barbed ends of actin filaments, effectively preventing the addition of new actin monomers and disrupting the dynamic process of actin polymerization [8]. This molecular intervention compromises the formation and function of microfilaments, which are essential for cytokinesis and polar body extrusion. During SCNT protocols, this translates to CB's crucial role in inhibiting the extrusion of the second polar body following artificial activation of reconstructed oocytes, thereby preserving the diploid chromosome complement necessary for normal embryonic development [9] [10]. The integrity of this process is fundamental to SCNT success, as improper chromosome segregation can lead to aneuploidy and subsequent developmental failure.

JNJ-7706621: The Dual-Kinase Targeting Agent

JNJ-7706621 represents a more recently investigated approach with a distinct molecular target profile. This synthetic compound functions as a potent inhibitor of cyclin-dependent kinase 1 (CDK1) and Aurora kinases, with IC50 values of 9 nM and 11-15 nM respectively [11]. In the context of SCNT, inhibition of CDK1 directly reduces the activity of M-phase-promoting factor (MPF), a key regulator of meiotic resumption and cell cycle progression [3]. This targeted kinase inhibition creates a more favorable intracellular environment for nuclear reprogramming by modulating the phosphorylation status of critical substrates. Research indicates that JNJ-treated embryos exhibit significantly elevated Tyr15 phosphorylation of CDK1 alongside reduced Thr161 phosphorylation and lower overall MPF levels, creating a biochemical environment that supports improved embryonic development compared to traditional CB treatment [3].

Performance Comparison: Quantitative Experimental Data

Pre-implantation Development Across Species

Table 1: In Vitro Development of SCNT Embryos Treated with Cytochalasin B or JNJ-7706621

Species	Treatment	Concentration	Blastocyst Rate	Total Cell Count	Apoptotic Cells	Citation
Porcine	Cytochalasin B	5 μg/mL	Baseline	51.0	Not reported	[9]
Porcine	JNJ-7706621	10 μM	Significantly higher vs. CB	Not reported	Not reported	[3]
Mouse	Cytochalasin B	5 μg/mL	39.9% ± 6.4	52.7 ± 3.6	Higher	[1]
Mouse	JNJ-7706621	10 μM	61.4% ± 4.4	70.7 ± 2.9	Reduced	[1]
Goat	Cytochalasin B	1.0 μg/mL	Improved vs. control	Not reported	Not reported	[10]

The comparative data reveal consistent advantages for JNJ-7706621 in supporting embryonic development across multiple species. In mouse models, JNJ treatment demonstrated a substantially higher blastocyst rate (61.4% vs. 39.9%) and generated blastocysts with significantly increased total cell numbers (70.7 vs. 52.7), suggesting enhanced embryonic quality and developmental potential [1]. Additionally, JNJ-treated embryos exhibited reduced apoptotic cell counts, indicating better embryo health. In porcine SCNT, both reagents showed effectiveness, with JNJ-7706621 producing a "significantly higher" blastocyst rate compared to CB treatment [3].

Post-Implantation and Full-Term Development Outcomes

Table 2: In Vivo Development of SCNT Embryos After Uterine Transfer

Development Parameter	Cytochalasin B	JNJ-7706621	Significance
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	P < 0.05
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	P < 0.05
Placental Weight (Mouse)	0.34 g	0.14 g (IVF control)	Not reported
Developmental Abnormalities	Variable by donor cell type	Not reported	[12] [13]

The most striking differences emerge in post-implantation development and live birth outcomes. Mouse SCNT experiments demonstrated that JNJ-7706621 treatment yielded significantly higher implantation rates (68.3% vs. 50.8%) and a dramatically improved live birth rate (10.9% vs. 2.4%) compared to conventional CB treatment [1]. This substantial increase in reproductive efficiency represents a potentially transformative advancement in SCNT technology. Additionally, CB-treated clones often exhibit placental abnormalities, with documented cases of remarkably heavier placentas in cloned mice (0.34g vs. 0.14g in IVF controls) [12]. The rate of developmental abnormalities in CB-based SCNT has been shown to vary significantly with donor cell type, ranging from 10.87% with fetal fibroblasts to 56.57% with adult fibroblasts [13].

Experimental Protocols and Workflows

Standard Cytochalasin B Treatment Protocol

The conventional CB protocol involves specific treatment windows during the nuclear transfer process. For porcine SCNT, effective results are achieved with 7.5 μg/mL CB for 3 hours immediately following electrical activation [9]. This treatment duration and concentration effectively prevent second polar body extrusion in approximately 65% of oocytes compared to only 17% in untreated controls. In caprine species, research indicates that CB treatment for 2-3 hours between fusion and activation significantly improves in vitro and in vivo development of NT embryos by reducing the fragmentation rate [10]. The concentration optimization studies in mice demonstrate that while higher CB concentrations (4-5 μg/mL) can induce small fragments in embryos, lower concentrations (2.5 μg/mL) produce optimal results with minimal fragmentation [12].

JNJ-7706621 Treatment Protocol

The emerging protocol for JNJ-7706621 application utilizes 10 μM concentration for 4 hours post-activation to achieve optimal results in both porcine and mouse SCNT embryos [3] [1]. This relatively brief exposure window effectively modulates the kinase activity without prolonged chemical exposure that might compromise embryo viability. The treatment timing coincides with critical early reprogramming events, facilitating more successful epigenetic remodeling. Research indicates this specific treatment regimen significantly improves blastocyst formation rates and quality while reducing structural abnormalities in both porcine and mouse models compared to CB treatment [3] [1].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for SCNT Embryo Research

Reagent/Solution	Function in SCNT	Typical Working Concentration	Considerations
Cytochalasin B	Prevents polar body extrusion by inhibiting actin polymerization	2.5-7.5 μg/mL (species-dependent)	Higher concentrations (>4μg/mL) may cause fragmentation; requires optimization
JNJ-7706621	Enhances reprogramming via CDK1 and Aurora kinase inhibition	10 μM for 4 hours	Improved blastocyst quality and live birth rates; newer with less extensive validation
Trichostatin A (TSA)	Histone deacetylase inhibitor for epigenetic reprogramming	50 nM for 24 hours	Synergistic effect when combined with CB; improves blastocyst rates
Strontium Chloride (SrCl₂)	Artificial oocyte activation	5-10 mM in Ca²⁺-free medium	Concentration affects second polar body extrusion rates
Hyaluronidase	Cumulus cell removal from oocytes	300 unit/mL	Essential for oocyte denuding before enucleation
Closantel-13C6	Closantel-13C6, CAS:1325559-20-3, MF:C22H14Cl2I2N2O2, MW:669.0 g/mol	Chemical Reagent	Bench Chemicals
Lansoprazole thiadiazine impurity	Lansoprazole thiadiazine impurity, CAS:1781244-56-1, MF:C23H16F3N5OS, MW:467.5 g/mol	Chemical Reagent	Bench Chemicals

The comparative analysis between cytochalasin B and JNJ-7706621 reveals a nuanced landscape for SCNT research. Cytochalasin B remains the conventional workhorse with extensive historical validation across numerous species, well-characterized protocols, and reliable performance in preventing polar body extrusion. However, emerging evidence positions JNJ-7706621 as a promising alternative that may address some fundamental limitations of traditional CB approach, particularly regarding epigenetic reprogramming and full-term developmental competence.

The selection between these reagents should be guided by specific research objectives. For established SCNT protocols where maintenance of diploidy is the primary concern, CB provides a proven, cost-effective option. For investigations prioritizing enhanced reprogramming efficiency, improved blastocyst quality, and increased live birth outcomes, JNJ-7706621 offers compelling advantages. Future research directions should explore potential synergistic effects of combining cytoskeletal stabilization with kinase inhibition, as well as optimized treatment windows that maximize reprogramming potential while minimizing technical artifacts. As the field advances toward more efficient nuclear transfer methodologies, the mechanistic understanding derived from both approaches will continue to inform the development of next-generation SCNT protocols.

Somatic cell nuclear transfer (SCNT) represents a pivotal technology in animal cloning, regenerative medicine, and developmental biology research. However, a significant limitation hindering its widespread application is the reduced developmental potential of SCNT embryos compared to those from natural reproduction. The efficiency of producing viable, full-term offspring remains disappointingly low, primarily due to defective nuclear reprogramming and cytoskeletal abnormalities that occur during the cloning process.

A critical step in SCNT protocols involves preventing premature exit from the cell cycle after oocyte activation. For decades, cytochalasin B (CB) has been the standard cytoskeletal inhibitor used for this purpose, working primarily by disrupting actin filament polymerization. However, growing evidence suggests CB provides suboptimal conditions for subsequent embryonic development. The emergence of JNJ-7706621 as a dual-specificity inhibitor targeting both cyclin-dependent kinase 1 (CDK1) and Aurora kinases offers a novel approach that addresses both cell cycle regulation and chromosomal stability simultaneously. This article provides a comprehensive comparison of these two compounds within the context of SCNT embryo development, evaluating their mechanisms, efficacy, and practical applications in cloning research.

Comparative Analysis: JNJ-7706621 vs. Cytochalasin B

Mechanistic Profiles and Molecular Targets

The fundamental difference between JNJ-7706621 and cytochalasin B lies in their mechanisms of action at the molecular level, which translates to significantly different outcomes in SCNT efficiency.

JNJ-7706621 is a sophisticated small molecule inhibitor that simultaneously targets two crucial classes of cell cycle regulators. It potently inhibits CDK1 (IC50 = 9 nM) and CDK2 (IC50 = 3 nM), which are central drivers of cell cycle progression, particularly the G2/M transition. Additionally, it strongly inhibits Aurora A (IC50 = 11 nM) and Aurora B (IC50 = 15 nM), kinases essential for proper chromosome segregation and spindle assembly during mitosis [14] [15]. This dual mechanism allows JNJ-7706621 to effectively arrest the cell cycle while promoting chromosomal stability—a critical combination for successful nuclear reprogramming in SCNT.

In contrast, cytochalasin B functions primarily as a cytoskeletal disruptor, specifically inhibiting actin polymerization by capping the fast-growing end of actin filaments. While this effectively prevents premature extrusion of the donor nucleus (pseudo-polar body extrusion) during SCNT, it does not directly address cell cycle regulation or chromosomal stability issues [16]. This fundamental limitation explains why CB-treated embryos often exhibit developmental defects despite successful initial nuclear transfer.

Table 1: Molecular Mechanisms and Primary Targets

Compound	Primary Targets	Mechanism of Action	Cellular Effects
JNJ-7706621	CDK1, CDK2, Aurora A, Aurora B	Dual inhibition of cell cycle kinases and chromosomal stability regulators	Cell cycle arrest, improved spindle formation, reduced chromosomal abnormalities
Cytochalasin B	Actin filaments	Inhibition of actin polymerization	Cytoskeletal disruption, prevention of pseudo-polar body extrusion

Quantitative Developmental Outcomes

Recent studies directly comparing these compounds in SCNT protocols reveal striking differences in embryonic development outcomes. In mouse SCNT experiments, post-activation treatment with 10 μM JNJ-7706621 significantly enhanced preimplantation development compared to standard CB treatment (61.4% ± 4.4 vs. 39.9% ± 6.4) [1]. More importantly, JNJ-7706621 treatment yielded substantial improvements in critical blastocyst quality parameters, including increased total cell numbers (70.7 ± 2.9 vs. 52.7 ± 3.6), inner cell mass cells (15.4 ± 1.1 vs. 10.4 ± 0.7), and trophectoderm cells (55.3 ± 2.5 vs. 42.3 ± 3.3) [1].

The most compelling evidence for JNJ-7706621's superiority comes from full-term development outcomes, which represent the ultimate test of SCNT efficiency. JNJ-treated embryos demonstrated dramatically higher implantation rates (68.3% ± 4.3 vs. 50.8% ± 3.7) and live birth rates (10.9% ± 2.8 vs. 2.4% ± 2.4) compared to CB-treated embryos [1]. This nearly 5-fold increase in live offspring represents a significant advancement in cloning technology.

Similar advantages have been observed in porcine SCNT models, where JNJ-7706621 treatment significantly improved blastocyst formation rates compared to CB, suggesting its benefits extend across multiple species [3]. The consistency of these improvements across developmental stages and species underscores the fundamental advantages of JNJ-7706621's targeted mechanism.

Table 2: Quantitative Comparison of Embryonic Development Outcomes in Mouse SCNT

Development Parameter	Cytochalasin B	JNJ-7706621	Improvement
Blastocyst Development Rate	39.9% ± 6.4	61.4% ± 4.4	+21.5%
Total Blastocyst Cell Count	52.7 ± 3.6	70.7 ± 2.9	+18.0 cells
Inner Cell Mass Cells	10.4 ± 0.7	15.4 ± 1.1	+5.0 cells
Trophectoderm Cells	42.3 ± 3.3	55.3 ± 2.5	+13.0 cells
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	+17.5%
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	+8.5% (4.5-fold)

Experimental Protocols and Methodologies

Standardized SCNT Protocol with JNJ-7706621

The following protocol has been optimized for mouse SCNT based on published methodologies [1] [17]:

Oocyte Collection and Enucleation:

• Collect metaphase II oocytes from 6-8 week old B6D2F1 female mice 15 hours post-hCG injection.
• Perform enucleation in Hepes-CZB medium (HCZB) containing 10 μg/ml cytochalasin B at 37°C.
• Remove the MII spindle-complex using a piezo-actuated micromanipulator with a 6-8 μm enucleation pipette.
• Transfer enucleated oocytes to HCZB washing medium, then hold in KSOM culture medium for up to 30 minutes.

Donor Cell Injection:

• Prepare donor cumulus cells in TCM-washing medium mixed with 12% polyvinylpyrrolidone.
• Transfer 12-15 enucleated oocytes to a 10 μl droplet of HCZB with 10 μg/ml CB.
• Introduce a single donor cell into each oocyte using piezo pulses and the hole-sealing technique [17].
• Stabilize reconstructed oocytes in room temperature HCZB for 10 minutes before activation.

Activation and JNJ-7706621 Treatment:

• Activate reconstructed oocytes in calcium-free CZB with 10 mM SrClâ‚‚ and 5 μg/ml CB for 5.5 hours.
• Treat with 10 μM JNJ-7706621 for 4 hours immediately post-activation.
• Wash treated oocytes in HCZB and culture in KSOM medium under humidified conditions at 37°C for 4 days.

Protocol Modifications for Porcine SCNT

For porcine SCNT, similar principles apply with slight modifications [3]:

• Treat parthenogenetically activated or SCNT embryos with 10 μM JNJ-7706621 for 4 hours post-activation.
• Culture embryos in PZM-3 or NCSU-23 medium at 38.5°C in 5% COâ‚‚.
• Assess blastocyst development on Day 5-7 post-activation.

Signaling Pathways and Mechanism of Action

The molecular pathways through which JNJ-7706621 enhances SCNT efficiency involve coordinated regulation of both cell cycle progression and chromosomal segregation machinery. The following diagram illustrates the key mechanisms and their functional outcomes in SCNT embryos:

JNJ-7706621 primarily functions through two parallel mechanisms that converge to improve SCNT outcomes. First, its inhibition of CDK1 and CDK2 leads to reduced M-phase promoting factor (MPF) activity and altered CDK1 phosphorylation status at Tyr15 and Thr161 residues [3]. This effectively maintains the reconstructed embryo in a state conducive to nuclear reprogramming. Second, its simultaneous inhibition of Aurora A and Aurora B promotes proper spindle assembly and accurate chromosome segregation, significantly reducing aneuploidy and other chromosomal abnormalities common in SCNT embryos [1] [15].

Additionally, JNJ-7706621 treatment demonstrates unexpected benefits for cytoskeletal integrity. Unlike cytochalasin B, which disrupts actin organization, JNJ-7706621 reduces aberrant F-actin and tubulin structures and decreases blastomere fragmentation in two-cell SCNT embryos [1]. This comprehensive activity profile addresses multiple bottlenecks in SCNT efficiency simultaneously, explaining its superior performance compared to conventional CB treatment.

The Scientist's Toolkit: Essential Research Reagents

Successful implementation of JNJ-7706621 in SCNT research requires several key reagents and appropriate controls. The following table outlines the essential components:

Table 3: Essential Research Reagents for SCNT Studies with JNJ-7706621

Reagent/Chemical	Concentration Used	Function in Protocol	Key Considerations
JNJ-7706621	10 μM in culture medium	Post-activation treatment to enhance developmental competence	Dissolve in DMSO; store at -20°C; avoid freeze-thaw cycles
Cytochalasin B	5-10 μg/mL in HCZB	Cytoskeletal inhibitor during enucleation and nuclear injection	Light-sensitive; prepare fresh stock solutions
Hepes-CZB Medium (HCZB)	N/A	Manipulation medium for enucleation and injection	Maintain at 37°C during procedures
KSOM Medium	N/A	Culture medium for preimplantation development	Equilibrate in 5% COâ‚‚ overnight before use
SrCl₂	10 mM in Ca²⁺-free CZB	Parthenogenetic activation agent	Use with CB for activation control groups
Polyvinylpyrrolidone (PVP)	12% in TCM-washing	Viscosity modifier for donor cell handling	Reduces stickiness during cell manipulation
(R)-3-(bromomethyl)hexanoic acid	(R)-3-(Bromomethyl)hexanoic Acid|CAS 1942054-60-5	High-purity (R)-3-(Bromomethyl)hexanoic acid, a key chiral building block for Brivaracetam synthesis. This product is for research use only and not for human consumption.	Bench Chemicals
Migoprotafib	GDC-1971 SHP2 Inhibitor|For Research Use	GDC-1971 is a potent, selective allosteric SHP2 inhibitor for cancer research. For Research Use Only. Not for human or veterinary use.	Bench Chemicals

When designing experiments, researchers should include both JNJ-7706621 treatment groups and cytochalasin B control groups to enable direct comparison of developmental outcomes. For mechanistic studies, additional assessments of spindle morphology, chromosome alignment, actin organization, and DNA damage markers are recommended to fully characterize treatment effects [1].

The comprehensive comparison between JNJ-7706621 and cytochalasin B demonstrates a clear superiority of the novel kinase inhibitor across multiple metrics of SCNT success. By simultaneously addressing both cell cycle regulation and chromosomal stability—two fundamental challenges in nuclear transfer—JNJ-7706621 represents a significant advancement over conventional cytoskeletal disruptors.

The 5-fold increase in live birth rates observed in mouse SCNT, coupled with improved blastocyst quality and implantation efficiency, positions JNJ-7706621 as a transformative reagent for cloning and embryo biotechnology applications [1]. Its efficacy across multiple species (murine and porcine) suggests broad applicability in both basic research and agricultural biotechnology.

Future research directions should focus on optimizing treatment timing and duration, exploring potential synergistic combinations with other reprogramming enhancers, and investigating the molecular mechanisms underlying its beneficial effects on cytoskeletal organization. As the field moves toward more efficient nuclear transfer techniques, JNJ-7706621 provides a powerful tool for unraveling the complexities of nuclear reprogramming while offering immediate practical benefits for improving SCNT outcomes.

Somatic cell nuclear transfer (SCNT) represents a powerful technology for reprogramming differentiated somatic cells into totipotent embryos, yet its application remains hampered by consistently low efficiency. A key determinant of successful embryonic reprogramming lies in the proper maintenance of cytoskeletal integrity, which extends beyond its traditional structural roles to directly influence nuclear architecture, chromatin organization, and gene expression patterns. Within this paradigm, the choice of post-activation treatment in SCNT protocols becomes critical. This guide objectively compares the performance of JNJ-7706621, a specific inhibitor of cyclin-dependent kinase 1 (CDK1) and aurora kinases, against the traditionally used cytochalasin B (CB), examining their mechanistic impacts on cytoskeletal dynamics and subsequent embryonic development. Emerging research positions cytoskeletal proteins as fundamental regulators of nuclear function, with actin comprising approximately 20% of the total cellular actin within the nucleus, where it contributes to chromatin remodeling complexes, transcription machinery, and genome organization [18]. The integrity of this nuclear-cytoskeletal network therefore provides a crucial foundation for the extensive epigenetic reprogramming required after nuclear transfer.

Comparative Performance Data: JNJ-7706621 vs. Cytochalasin B

Quantitative Developmental Outcomes

Direct comparison of JNJ-7706621 and cytochalasin B in mouse SCNT models reveals substantial differences in embryonic developmental competence. The data below summarize key performance metrics from controlled studies.

Table 1: Developmental Outcomes of Mouse SCNT Embryos Treated with JNJ-7706621 vs. Cytochalasin B

Developmental Parameter	Cytochalasin B (CB)	JNJ-7706621 (JNJ)	Significance
Blastocyst Development Rate	39.9% ± 6.4	61.4% ± 4.4	Improved with JNJ [1]
Total Blastocyst Cell Number	52.7 ± 3.6	70.7 ± 2.9	Improved with JNJ [1]
Inner Cell Mass (ICM) Cells	10.4 ± 0.7	15.4 ± 1.1	Improved with JNJ [1]
Trophectoderm (TE) Cells	42.3 ± 3.3	55.3 ± 2.5	Improved with JNJ [1]
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	Improved with JNJ [1]
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	Improved with JNJ [1]

Similar enhancements were observed in porcine models, where JNJ-7706621 treatment significantly improved blastocyst development rates for both parthenogenetically activated and SCNT embryos compared to cytochalasin B treatment [3]. The consistency of these benefits across species underscores the fundamental nature of the mechanistic advantages.

Cytoskeletal and Chromosomal Integrity

Beyond developmental rates, the treatments differ markedly in their effects on subcellular architecture, which directly impacts reprogramming efficiency.

Table 2: Cytoskeletal and Chromosomal Integrity Parameters

Parameter	Cytochalasin B	JNJ-7706621	Biological Impact
F-actin Organization	Aberrant patterns	Significantly improved	Better cellular structure [1]
Tubulin Organization	Aberrant patterns	Significantly improved	Proper spindle formation [1]
Spindle Abnormalities	Higher incidence	Significantly reduced	Proper chromosome segregation [1]
Blastomere Fragmentation	Present	Significantly reduced	Healthier cell divisions [1]
DNA Damage in 2-cell Embryos	Present	Significantly reduced	Enhanced genomic integrity [1]

The superior performance of JNJ-7706621 across these parameters demonstrates its comprehensive benefits for maintaining the structural framework necessary for successful reprogramming.

Mechanistic Insights: How Cytoskeletal Integrity Governs Reprogramming Success

Distinct Molecular Targets and Pathways

The fundamental difference between these compounds lies in their molecular targets and consequent effects on the cytoskeletal-nuclear axis.

JNJ-7706621 targets the core cell cycle regulators CDK1 and Aurora kinases, leading to reduced M-phase-promoting factor (MPF) activity [3]. This controlled cell cycle arrest provides a favorable window for nuclear remodeling while preserving cytoskeletal integrity. In contrast, cytochalasin B directly disrupts actin polymerization, compromising the structural foundation necessary for proper nuclear organization and gene regulation [18].

Nuclear-Cytoskeletal Crosstalk in Reprogramming

The connection between cytoskeletal integrity and nuclear reprogramming extends beyond mere structural support. The cytoskeleton serves as a dynamic regulator of nuclear architecture, directly influencing genome organization and gene expression patterns—critical factors in epigenetic reprogramming.

Nuclear actin, in particular, plays essential roles in chromatin remodeling complexes, transcription regulation, and genome organization [18]. It contributes to heterochromatin maintenance and proper deposition of chromatin regulators like Brg1 (SMARCA4), which is known to be involved in nuclear reprogramming [18]. When cytoskeletal integrity is compromised through suboptimal treatments, these essential nuclear functions are disrupted, creating a barrier to complete reprogramming.

The perinuclear cytoskeleton (pnCSK) constitutes a specialized mechanical compartment with properties distinct from other cytoplasmic regions, serving as a protective safeguard for the nucleus against mechanical perturbations [19] [20]. This protective function ensures stable nuclear environment conducive to the precise epigenetic modifications required for reprogramming.

Experimental Protocols for SCNT Optimization

Standardized Treatment Protocol for JNJ-7706621

Based on the published literature, the following protocol optimizes JNJ-7706621 treatment for SCNT embryos:

Post-Activation Treatment:

• Prepare JNJ-7706621 at a concentration of 10 μM in appropriate embryo culture medium [1] [3].
• Treat reconstructed SCNT embryos for 4 hours immediately following activation [3].
• Conduct treatment under standard embryo culture conditions (37°C, 5% COâ‚‚) [1].
• After treatment, wash embryos thoroughly and transfer to fresh culture medium for continued development.

Control Setup:

• For comparative studies, include a control group treated with cytochalasin B at 5 μg/mL for the same duration [1] [9].
• Additional controls may include non-treated SCNT embryos and parthenogenetically activated embryos [3].

Assessment Methodology

Primary Endpoints:

• Embryonic development rates at 24h (2-cell), 72h (morula), and 96h (blastocyst) [1]
• Blastocyst quality metrics: total cell count, inner cell mass (ICM):trophectoderm (TE) ratio [1]
• Live birth rates following embryo transfer [1]

Cytoskeletal and Nuclear Integrity Assessment:

• Immunofluorescence staining for F-actin (phalloidin) and tubulin at one-cell stage [1]
• Spindle morphology analysis through α-tubulin and DNA co-staining [1]
• DNA damage assessment in two-cell embryos via γH2AX staining [1]
• Apoptosis analysis in blastocysts using TUNEL assay [1]

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for SCNT Cytoskeletal Research

Reagent/Chemical	Function in SCNT Research	Application Notes
JNJ-7706621	Dual CDK1/Aurora kinase inhibitor; promotes proper cytoskeletal organization during reprogramming	Use at 10 μM for 4h post-activation; optimal for mouse and porcine models [1] [3]
Cytochalasin B	Actin polymerization inhibitor; prevents premature cytokinesis but disrupts cytoskeletal integrity	Traditional use at 5-7.5 μg/mL for 3-4h; serves as comparative control [1] [9]
Trichostatin A (TSA)	Histone deacetylase inhibitor; enhances epigenetic reprogramming when combined with cytoskeletal modulators	Used at 50 nM for 24h post-activation; synergistic with optimized cytoskeletal treatments [9]
Phalloidin Conjugates	High-affinity F-actin staining; assesses actin filament organization and integrity	Critical for quantifying cytoskeletal improvements; use with confocal microscopy [1] [20]
Anti-α-Tubulin Antibodies	Microtubule network visualization; evaluates spindle formation and chromosome segregation	Essential for assessing mitotic fidelity in reconstructed embryos [1]
TUNEL Assay Kits	Apoptosis detection in preimplantation embryos; measures embryo health and quality	Quantitative metric for treatment safety and embryo viability [1]
TMPyP4 tosylate	TMPyP4 tosylate, MF:C51H45N8O3S+3, MW:850.0 g/mol	Chemical Reagent
Olesoxime	Olesoxime, Z-|Mitochondrial-Targeted Research Compound

The comparative data demonstrate that JNJ-7706621 represents a significant advancement over traditional cytochalasin B for SCNT applications. By targeting specific cell cycle regulators while preserving cytoskeletal integrity, JNJ-7706621 creates a more favorable environment for the complex nuclear remodeling required during reprogramming. The mechanistic evidence indicates that maintaining proper cytoskeletal-nuclear connections is not merely supportive but fundamentally instrumental to reprogramming success, influencing chromatin organization, gene expression, and epigenetic resetting. For researchers aiming to optimize SCNT protocols, the strategic implementation of JNJ-7706621 as a post-activation treatment offers substantially improved developmental outcomes, higher-quality blastocysts, and significantly enhanced live birth rates across multiple species models.

Protocol Deep Dive: Optimizing Concentration and Treatment for Maximum Efficacy

Somatic cell nuclear transfer (SCNT) is a pivotal technology in animal cloning and regenerative medicine, yet its efficiency remains hampered by poor embryonic developmental competence. A critical step in the SCNT protocol is the post-activation treatment, designed to stabilize the reconstructed embryo and prevent aberrant chromosomal segregation. For years, the cytoskeletal inhibitor cytochalasin B (CB) has been the standard reagent for this purpose. However, recent research introduces JNJ-7706621 (JNJ), a specific inhibitor of cyclin-dependent kinase 1 (CDK1) and Aurora kinases, as a superior alternative. This guide objectively compares the performance of JNJ-7706621 against cytochalasin B, consolidating the most current experimental data to establish a new gold standard for concentration and timing in SCNT embryo development research.

Head-to-Head Comparison: JNJ-7706621 vs. Cytochalasin B

Direct comparative studies reveal that JNJ-7706621 consistently outperforms cytochalasin B across multiple species and developmental stages. The table below summarizes the key quantitative outcomes from recent research.

Table 1: Comparative Developmental Outcomes of SCNT Embryos Treated with JNJ-7706621 vs. Cytochalasin B

Developmental Parameter	Cytochalasin B (CB)	JNJ-7706621 (JNJ)	Significance & Context
Blastocyst Formation Rate (Mouse)	39.9% ± 6.4 [1] [2]	61.4% ± 4.4 [1] [2]	Significantly higher with JNJ treatment [1] [2]
Blastocyst Formation Rate (Pig)	Lower than JNJ [3]	Higher than CB [3]	Significantly improved with JNJ [3]
Total Blastocyst Cell Number (Mouse)	52.7 ± 3.6 [1] [2]	70.7 ± 2.9 [1] [2]	Significantly increased with JNJ [1] [2]
Inner Cell Mass (ICM) Cells (Mouse)	10.4 ± 0.7 [1] [2]	15.4 ± 1.1 [1] [2]	Significantly increased with JNJ [1] [2]
Trophectoderm (TE) Cells (Mouse)	42.3 ± 3.3 [1] [2]	55.3 ± 2.5 [1] [2]	Significantly increased with JNJ [1] [2]
Implantation Rate (Mouse)	50.8% ± 3.7 [1] [2]	68.3% ± 4.3 [1] [2]	Significantly higher with JNJ [1] [2]
Full-Term Live Birth Rate (Mouse)	2.4% ± 2.4 [1] [2]	10.9% ± 2.8 [1] [2]	Significantly higher with JNJ [1] [2]
Blastomere Fragmentation & DNA Damage	Present [1] [2]	Significantly Reduced [1] [2]	JNJ enhances chromosomal stability [1] [2]
Cytoskeletal Integrity (F-actin/Tubulin)	Aberrant patterns observed [1] [2]	Significantly reduced aberrations [1] [2]	JNJ improves spindle normality and cytoskeleton organization [1] [2]

Establishing the Gold Standard: Optimal Concentration and Timing

The efficacy of JNJ-7706621 is highly concentration-dependent. Research identifies a clear optimal window for its use.

Table 2: Established Gold Standard Protocol for JNJ-7706621

Parameter	Gold Standard	Experimental Evidence
Optimal Concentration	10 μM	In mouse studies, 10 μM JNJ yielded significantly higher developmental competence to the blastocyst stage compared to 1 μM and 50 μM. The 10 μM treatment also resulted in the highest live birth rate [1] [2].
Optimal Treatment Duration	4 hours post-activation	A treatment period of 4 hours post-activation was used effectively in porcine SCNT and parthenogenetic activation embryos [3].
Treatment Timing	Immediately after embryo activation	The treatment is applied as a post-activation intervention, replacing CB in the protocol [1] [2].

Detailed Experimental Protocols

To ensure reproducibility, here are the summarized methodologies from the key studies supporting the gold standard.

Protocol 1: Mouse SCNT as Described by Kang et al. (2025)

• Oocyte Collection & Enucleation: Collect metaphase II (MII) oocytes from superovulated B6D2F1 mice. Enucleate in HEPES-buffered CZB medium containing 5 μg/mL CB [12].
• Nuclear Transfer: Inject a single cumulus cell nucleus into the enucleated oocyte using a piezo-driven pipette [12].
• Activation & Treatment: Activate the reconstructed oocytes in Ca²⁺-free CZB medium containing 10 mM SrClâ‚‚. Subsequently, culture the activated embryos in KSOM medium supplemented with 10 μM JNJ-7706621 for a total of 6 hours post-activation [1] [2].
• In Vitro Culture (IVC): After treatment, wash the embryos and culture them in fresh KSOM medium at 37°C under 5% COâ‚‚. Assess development to the 2-cell, 4-cell, morula, and blastocyst stages [1] [12].
• Embryo Transfer: Transfer developing blastocysts into the uteri of pseudo-pregnant ICR surrogate females on day 3.5 of pregnancy to assess in vivo development and live birth rates [1] [2].

Protocol 2: Porcine SCNT and Parthenogenesis as Described by Guo et al. (2018)

• Oocyte Maturation: In vitro-mature porcine oocytes to the MII stage.
• SCNT/Activation: Perform somatic cell nuclear transfer or induce parthenogenetic activation (PA).
• JNJ-7706621 Treatment: Expose the reconstructed PA or SCNT embryos to 10 μM JNJ-7706621 for 4 hours immediately following activation [3].
• In Vitro Culture: Culture the treated embryos in porcine zygote medium-3 (PZM-3) and evaluate blastocyst formation rates on Day 7 [3].

Mechanisms of Action: A Visual Guide

The superior performance of JNJ-7706621 is rooted in its targeted mechanism of action, which fundamentally differs from that of cytochalasin B. The following diagrams illustrate these key differences.

Diagram 1: Mechanisms of action for Cytochalasin B and JNJ-7706621.

JNJ-7706621's action on key kinases initiates a cascade of molecular events that underpin its success. The following pathway details this signaling logic and the subsequent physiological outcomes in the embryo.

Diagram 2: JNJ-7706621 signaling pathway and embryonic outcomes.

The Scientist's Toolkit: Essential Research Reagents

This table lists the key reagents and their functions as used in the established JNJ-7706621 protocol, providing a quick reference for experimental setup.

Table 3: Essential Research Reagents for SCNT with JNJ-7706621

Reagent/Solution	Function in the Protocol	Exemplary Concentration
JNJ-7706621	CDK1 and Aurora kinase inhibitor used for post-activation treatment to improve developmental competence.	10 μM [3] [1] [2]
Cytochalasin B (CB)	Cytoskeletal inhibitor used for enucleation and as a control in comparative studies.	5 μg/mL [1] [12] [2]
SrClâ‚‚ (Strontium Chloride)	Chemical agent used for artificial oocyte activation.	5-10 mM [12]
KSOM Medium	Potassium-supplemented simplex optimized medium; used for the in vitro culture of mouse embryos post-activation.	N/A [1] [12]
HEPES-buffered CZB Medium	Handling medium used for enucleation and nuclear transfer procedures.	N/A [12]
PZM-3 Medium	Porcine zygote medium; used for the in vitro culture of porcine embryos.	N/A [3]
QAQ dichloride	QAQ dichloride, MF:C28H44Cl2N6O2, MW:567.6 g/mol	Chemical Reagent
Cyclophilin inhibitor 1	Cyclophilin inhibitor 1, MF:C31H39N5O7, MW:593.7 g/mol	Chemical Reagent

The consolidated data from recent, rigorous studies compellingly argue for a paradigm shift in SCNT methodology. JNJ-7706621, at a concentration of 10 μM applied for 4-6 hours post-activation, establishes a new gold standard, decisively outperforming the traditional use of cytochalasin B. Its targeted mechanism, which directly addresses the core issues of cell cycle regulation and genomic integrity in cloned embryos, translates into superior pre-implantation development, enhanced blastocyst quality, and, most critically, a significantly higher yield of live offspring. For researchers aiming to optimize cloning efficiency and achieve robust, reproducible results, the adoption of JNJ-7706621 is a strategically justified advancement.

Somatic Cell Nuclear Transfer (SCNT) represents a pivotal technology in reproductive biology, regenerative medicine, and transgenic animal production. However, the technique faces significant challenges due to low embryonic developmental rates and high incidences of epigenetic abnormalities. A critical step in the SCNT protocol involves the artificial activation of reconstructed embryos to initiate development, a process where cytoskeletal stabilizers and cell cycle regulators play a crucial role. For decades, Cytochalasin B has been the standard reagent used during SCNT activation to prevent premature extrusion of chromosomes by inhibiting microfilament polymerization. More recently, JNJ-7706621—a dual-specific inhibitor of cyclin-dependent kinase 1 (CDK1) and Aurora kinases—has emerged as a promising alternative with potential to enhance developmental outcomes. This guide provides a systematic, data-driven comparison of these two compounds, offering researchers evidence-based insights for protocol optimization.

Compound Profiles and Mechanisms of Action

JNJ-7706621: A Targeted Cell Cycle Inhibitor

JNJ-7706621 is a small molecule inhibitor that primarily targets CDK1 and Aurora kinases, key regulators of the cell cycle [21]. Its application in SCNT protocols exploits its ability to suppress M-phase-promoting factor (MPF) activity, a crucial barrier to successful reprogramming after nuclear transfer. By inhibiting CDK1, JNJ-7706621 induces a temporary cell cycle arrest that enhances nuclear reprogramming and promotes proper embryonic genome activation [3] [1].

Cytochalasin B: A Cytoskeletal Disruptor

Cytochalasin B is a fungal metabolite that primarily targets actin polymerization by binding to the growing end of F-actin filaments and preventing their elongation [22] [23]. In SCNT protocols, it serves a mechanical function by preventing premature chromosome extrusion during the activation process, thereby maintaining ploidy. However, its mechanism involves disruption of fundamental cellular processes including cell adhesion, morphology, and intracellular transport [22] [24].

Comparative Mechanism Visualization

The following diagram illustrates the distinct pathways through which JNJ-7706621 and Cytochalasin B exert their effects on SCNT embryos:

Figure 1: Distinct mechanistic pathways of JNJ-7706621 and Cytochalasin B in SCNT embryo development. JNJ-7706621 (green pathway) targets cell cycle regulation while Cytochalasin B (red pathway) affects cytoskeletal integrity.

Comparative Experimental Data

Preimplantation Development Outcomes

Multiple studies have directly compared the effects of JNJ-7706621 and Cytochalasin B on embryonic development across species. The table below summarizes key developmental parameters:

Table 1: Comparative developmental outcomes of SCNT embryos treated with JNJ-7706621 versus Cytochalasin B

Developmental Parameter	Species	JNJ-7706621 (10 μM)	Cytochalasin B (5 μg/mL)	P-value	Citation
Blastocyst Rate (%)	Porcine	Significantly higher	Control reference	<0.05	[3]
Blastocyst Rate (%)	Mouse	61.4% ± 4.4	39.9% ± 6.4	Significant	[1]
Total Cell Number	Mouse	70.7 ± 2.9	52.7 ± 3.6	Significant	[1]
Inner Cell Mass Cells	Mouse	15.4 ± 1.1	10.4 ± 0.7	Significant	[1]
Trophectoderm Cells	Mouse	55.3 ± 2.5	42.3 ± 3.3	Significant	[1]
Apoptotic Cells	Mouse	Significantly lower	Higher	Significant	[1]
Live Birth Rate (%)	Mouse	10.9% ± 2.8	2.4% ± 2.4	Significant	[1]

Epigenetic and Cellular Effects

Beyond developmental rates, the compounds demonstrate fundamentally different effects on cellular integrity and reprogramming:

Table 2: Cellular and epigenetic effects of JNJ-7706621 versus Cytochalasin B

Parameter	JNJ-7706621	Cytochalasin B
Abnormal Spindles	Significantly reduced	Higher incidence
Blastomere Fragmentation	Significantly reduced	More frequent
DNA Damage	Decreased	Increased
MPF Activity	Significantly reduced	No direct effect
Cytoskeletal Integrity	Preserved F-actin and tubulin	Disrupted microfilaments
Cell Surface Morphology	Normal	Rough, branched processes

Detailed Experimental Protocols

JNJ-7706621 Treatment Protocol

Optimal Concentration Determination:

• Prepare working concentrations of 1 μM, 10 μM, and 50 μM JNJ-7706621 in appropriate embryo culture medium [1]
• For porcine SCNT embryos: Use 10 μM for 4 hours post-activation [3]
• For mouse SCNT embryos: Use 10 μM as optimal concentration [1]

Step-by-Step Protocol:

• Perform standard SCNT procedure using donor cells and enucleated oocytes
• After reconstruction and fusion, activate embryos using appropriate activation method
• Immediately post-activation, transfer embryos to culture medium containing 10 μM JNJ-7706621
• Incubate for 4 hours at 38.5°C in a humidified atmosphere of 5% COâ‚‚
• After treatment, wash embryos thoroughly and transfer to fresh culture medium
• Continue culture under standard conditions until blastocyst stage (Day 7-9 depending on species)

Cytochalasin B Standard Protocol

Standard Concentration:

• Use 5 μg/mL in appropriate embryo culture medium [3] [1]

Step-by-Step Protocol:

• Complete SCNT reconstruction and fusion procedures
• Following activation, transfer embryos to medium containing 5 μg/mL Cytochalasin B
• Incubate for 4 hours at 37-38.5°C depending on species requirements
• Wash embryos thoroughly to remove Cytochalasin B completely
• Transfer to fresh culture medium for continued development

Experimental Workflow

The following diagram outlines the comparative experimental workflow for evaluating both compounds in SCNT protocols:

Figure 2: Experimental workflow for comparative analysis of JNJ-7706621 and Cytochalasin B in SCNT embryo development.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key reagents for SCNT embryo research with JNJ-7706621 and Cytochalasin B

Reagent	Function	Working Concentration	Key Considerations
JNJ-7706621	CDK1/Aurora kinase inhibitor; Reduces MPF activity; Improves reprogramming	10 μM for 4 hours	Dissolve in DMSO; Store at -20°C; Avoid repeated freeze-thaw cycles
Cytochalasin B	Actin polymerization inhibitor; Prevents chromosome extrusion	5 μg/mL for 4 hours	Light-sensitive; Cytotoxic at high concentrations; Reversible effects
Cytochalasin D	Alternative actin inhibitor; More potent than Cytochalasin B	0.5-1 μg/mL	Higher potency; Different solubility profile
Trichostatin A (TSA)	HDAC inhibitor; Epigenetic modifier	50 nM (varies by protocol)	Can be combined with JNJ-7706621 for synergistic effect [25]
5-Azacytidine	DNA demethylating agent	0.5-1.0 μM (donor cell treatment)	Can reduce developmental potential in SCNT [26]
S-adenosylhomocysteine	Methyltransferase inhibitor	0.5-1.0 mM (donor cell treatment)	Shows beneficial effects on SCNT development [26]
Golotimod TFA	Golotimod TFA, MF:C18H20F3N3O7, MW:447.4 g/mol	Chemical Reagent	Bench Chemicals
Rehmannioside A	Rehmannioside A | High Purity Reference Standard	High-purity Rehmannioside A for research. Explore its biochemical properties and applications. For Research Use Only. Not for human or veterinary use.	Bench Chemicals

Discussion and Protocol Recommendations

The comparative data clearly demonstrates that JNJ-7706621 outperforms Cytochalasin B across multiple developmental parameters in SCNT embryos. The significantly higher blastocyst formation rates, increased cell numbers, and dramatically improved live birth outcomes with JNJ-7706621 treatment highlight its superior efficacy. Mechanistically, while Cytochalasin B primarily serves a mechanical function in preventing chromosome loss, JNJ-7706621 addresses fundamental biological barriers to reprogramming by modulating cell cycle regulation and epigenetic remodeling.

For researchers establishing new SCNT protocols or optimizing existing ones, the following evidence-based recommendations are provided:

• For maximum developmental competence: Implement JNJ-7706621 at 10 μM for 4 hours post-activation as a replacement for Cytochalasin B
• For epigenetic enhancement: Consider combining JNJ-7706621 with Trichostatin A (50 nM) to further improve reprogramming efficiency [25]
• For donor cell preparation: Explore S-adenosylhomocysteine (0.5-1.0 mM) treatment of donor cells to reduce inhibitory methylation marks [26]
• When maintaining Cytochalasin B is necessary: Limit exposure time to 4 hours and ensure thorough washing post-treatment to minimize cytotoxic effects

The transition from Cytochalasin B to JNJ-7706621 represents a paradigm shift in SCNT methodology, moving from purely mechanical manipulation to targeted biological intervention. This approach addresses the core limitations of SCNT efficiency and holds significant promise for advancing reproductive technologies across multiple species.

Somatic cell nuclear transfer (SCNT) is a pivotal technique in reproductive biology, biotechnology, and therapeutic research, enabling the reprogramming of somatic cells into totipotent embryos. A critical step in the SCNT protocol is the artificial activation of the reconstructed embryo, which has traditionally relied on chemicals like cytochalasin B (CB) to ensure proper diploidy by suppressing polar body extrusion. While effective, the developmental outcomes of CB-treated SCNT embryos remain suboptimal, characterized by low blastocyst formation and live birth rates across many species. The recent introduction of JNJ-7706621 (JNJ), a dual inhibitor of cyclin-dependent kinase 1 (CDK1) and Aurora kinases, represents a promising alternative. Initial studies in mouse models have shown significant improvements, but the true translational value of any reagent lies in its efficacy across multiple species. This guide objectively compares the performance of JNJ-7706621 against the traditional cytochalasin B in porcine and other model systems, providing researchers with consolidated experimental data, protocols, and mechanistic insights to inform their experimental design.

Comparative Performance Data Across Species

The efficacy of JNJ-7706621 has been evaluated against cytochalasin B in several key model organisms. The table below summarizes the quantitative developmental outcomes from controlled studies.

Table 1: Comparative Developmental Outcomes of JNJ-7706621 vs. Cytochalasin B in SCNT

Species	Treatment	Blastocyst Rate (%)	Total Cell Number	Implantation Rate (%)	Live Birth Rate (%)	Citation
Mouse	JNJ-7706621 (10µM)	61.4 ± 4.4	70.7 ± 2.9	68.3 ± 4.3	10.9 ± 2.8	[1]
	Cytochalasin B (5µg/mL)	39.9 ± 6.4	52.7 ± 3.6	50.8 ± 3.7	2.4 ± 2.4	[1]
Porcine	JNJ-7706621 (10µM)	Significantly Higher*	N/D	N/D	N/D	[3]
	Cytochalasin B (5µg/mL)	Baseline*	N/D	N/D	N/D	[3]
Rat	JNJ-7706621	N/D	N/D	N/D	N/D	[27]
	Cytochalasin B (5µg/mL)	Used in protocols	N/D	N/D	N/D	[27]

N/D: No specific quantitative data reported in the search results for this parameter. * [3] reports a significantly higher blastocyst rate for JNJ-7706621 compared to CB but does not provide the exact baseline value.

The data demonstrates a clear trend: JNJ-7706621 consistently outperforms cytochalasin B in key metrics of embryonic health and developmental potential. In mouse models, the improvements are statistically significant and substantial, not only in pre-implantation development but also in critical post-implantation success metrics like implantation and live birth rates. The increased total cell count and inner cell mass cells in JNJ-treated blastocysts suggest a superior quality embryo, which is crucial for downstream applications. The positive results in porcine models, a species physiologically closer to humans, indicate the broader applicability and potential of JNJ-7706621 beyond murine systems [3].

Detailed Experimental Protocols

Standardized Treatment Workflow

The following diagram illustrates the general workflow for incorporating JNJ-7706621 or cytochalasin B into SCNT experiments, which is consistent across the cited studies.

Protocol Specifications for Different Species

The general workflow is adapted with specific parameters for different model organisms:

• Porcine SCNT Protocol (based on Guo et al., 2018) [3]:

  • Oocyte Source: In vitro-matured oocytes.
  • Activation Method: Typically, electrical pulse or calcium ionophore.
  • JNJ-7706621 Treatment: Immediately after activation, embryos are cultured in medium supplemented with 10µM JNJ-7706621 for 4 hours.
  • Control Group: Embryos treated with 5µg/mL cytochalasin B for 4 hours.
  • Post-Treatment: Embryos are washed and transferred to fresh culture medium for extended development until Day 7 for blastocyst assessment.

• Mouse SCNT Protocol (based on Theriogenology, 2025) [1]:

  • The treatment concentrations and timing are identical to the porcine protocol (10µM JNJ for 4h vs. 5µg/mL CB), demonstrating a standardized approach.
  • Assessment includes not only blastocyst rates but also detailed analysis of cytoskeletal integrity, DNA damage, and in vivo outcomes like implantation and live birth.

• Rat Embryo Considerations (based on PLoS One, 2010) [27]:

  • Rat embryos require more specific activation protocols than mice. While CB is commonly used in handling media, the study highlights that activation methods are not directly translatable even between closely related species. This underscores the need for empirical optimization when applying reagents like JNJ-7706621 in new models.

Mechanism of Action: JNJ-7706621 vs. Cytochalasin B

The superior performance of JNJ-7706621 is rooted in its fundamental molecular mechanism, which targets the core cell cycle machinery of the reconstructed embryo, unlike the cytoskeletal-targeting action of cytochalasin B.

Molecular Mechanism Diagram

Key Mechanistic Insights

• JNJ-7706621 as a Cell Cycle Regulator: JNJ-7706621 functions as a dual-specificity inhibitor. By targeting CDK1, it suppresses the activity of M-phase promoting factor (MPF), a key driver of the cell cycle. This promotes a synchronized exit from meiosis, which is crucial for proper pronuclear formation after activation [3] [15]. Concurrently, its inhibition of Aurora kinases safeguards against errors in chromosome segregation and spindle assembly, leading to the observed reductions in aneuploidy and DNA damage [1] [15].

• Cytochalasin B as a Cytoskeletal Disruptor: In contrast, cytochalasin B acts primarily by disrupting the dynamics of actin filaments (microfilaments). While this effectively blocks polar body extrusion and maintains diploidy, it is a mechanical intervention that does not address the underlying cell cycle misregulation. This often results in cytoskeletal abnormalities, which can contribute to blastomere fragmentation and compromised embryonic integrity [1] [28].

The Scientist's Toolkit: Essential Research Reagents

The following table catalogs the key reagents and their roles in conducting SCNT experiments with JNJ-7706621 and cytochalasin B.

Table 2: Essential Reagents for SCNT Embryo Research

Reagent / Material	Function / Role in SCNT	Example Usage in Context
JNJ-7706621	CDK1/Aurora kinase inhibitor; used for chemical-assisted embryo activation post-SCNT.	Post-activation treatment at 10µM for 4 hours to improve blastocyst development and quality in mouse and pig embryos [1] [3].
Cytochalasin B (CB)	Microfilament inhibitor; used for enucleation and to suppress polar body extrusion during activation.	Standard control treatment at 5µg/mL for 4 hours post-activation; also used in enucleation media [1] [28].
Demecolcine	Microtubule-depolymerizing agent; used for chemically assisted enucleation by inducing a protrusion containing chromosomes.	Alternative to mechanical enucleation; used at 0.4 µg/mL for 30 min to improve enucleation efficiency in goat and ovine SCNT [28].
MG-132	Proteasome inhibitor; prevents cyclin B degradation, aiding in enucleation and preventing spontaneous activation.	Can be used in combination with demecolcine (e.g., 2µM for 30 min) to improve the incidence of cytoplasmic protrusion in goat oocytes [28].
Kdm4b / Kdm4d	Histone H3K9me3 demethylases; epigenetic modifiers used to enhance reprogramming efficiency in SCNT embryos.	mRNA injection into SCNT embryos to remove reprogramming barriers and significantly improve developmental rates [29] [30].
Trichostatin A (TSA)	Histone deacetylase inhibitor (HDACi); epigenetic modifier used to improve gene expression reprogramming.	Treatment of SCNT embryos to enhance acetylation levels and support normal development, commonly used in primate cloning [31].
Betaxolol Hydrochloride	Betaxolol Hydrochloride	Betaxolol Hydrochloride is a cardioselective β1-adrenergic receptor antagonist for hypertension and glaucoma research. For Research Use Only. Not for human use.
Abacavir Sulfate	Abacavir Sulfate | Antiretroviral Reagent | RUO	Abacavir Sulfate for research: a potent nucleoside reverse transcriptase inhibitor (NRTI) for HIV/AIDS studies. For Research Use Only. Not for human consumption.

The comparative data from mouse and porcine models firmly establishes JNJ-7706621 as a superior alternative to cytochalasin B for enhancing SCNT embryo development. Its mechanism, which directly coordinates cell cycle exit and chromosomal stability, addresses fundamental shortcomings of the cytoskeletal-targeting approach of CB. This results in not only higher rates of blastocyst formation but, crucially, embryos of greater morphological and genomic quality, as evidenced by increased cell numbers and significantly higher live birth rates in mice.

For researchers working in porcine models or aspiring to translate SCNT techniques to other species, including non-human primates, the evidence supports the adoption of JNJ-7706621. Future research should focus on further optimizing treatment windows and combining JNJ-7706621 with other synergistic factors, such as epigenetic modulators like Kdm4d [29] [30], to push the boundaries of cloning efficiency. The consistent success of JNJ-7706621 across distinct species underscores its potential as a robust and effective tool in the pursuit of advanced reproductive and regenerative technologies.

Somatic cell nuclear transfer (SCNT) is a pivotal technology in animal cloning and regenerative medicine research. However, a significant challenge persists: SCNT embryos frequently exhibit reduced developmental potential compared to embryos from natural reproduction. This impairment manifests at various stages, from initial cleavage to full-term development, necessitating robust assessment metrics to evaluate interventions aimed at improving outcomes. The cytoskeleton, comprising structures like microtubules and microfilaments, plays a fundamental role in cell division, chromosome segregation, and cytokinesis. Its integrity is paramount for successful early embryonic development. Recently, the strategic use of small molecule inhibitors to enhance cytoskeletal function and chromosomal stability has emerged as a promising avenue. This guide provides a objective comparison between two such agents—JNJ-7706621 and the more established cytochalasin B (CB)—focusing on their impact on key metrics from cleavage to blastocyst quality in SCNT research.

Compound Profiles and Mechanisms of Action

JNJ-7706621: A Dual-Kinase Inhibitor

JNJ-7706621 is a specific inhibitor that targets both cyclin-dependent kinase 1 (CDK1) and aurora kinases. CDK1 is a central regulator of the cell cycle, particularly in the G2/M transition, while aurora kinases are crucial for spindle assembly and chromosome segregation. By inhibiting these kinases, JNJ modulates the activity of M-phase-promoting factor (MPF), a key driver of mitosis. Treatment with JNJ-7706621 leads to a suppression of CDK1 activity and a concomitant reduction in MPF levels, which appears to create a more favorable environment for proper nuclear remodeling and cytoskeletal organization in reconstructed embryos [3].

Cytochalasin B: An Actin Polymerization Inhibitor

Cytochalasin B is a well-known cell-permeable mycotoxin that functions primarily by inhibiting actin polymerization. It acts as a cytoskeletal relaxant, making the microfilament network less rigid. This property has made it a standard tool in embryology, not only in SCNT protocols to prevent premature cytokinesis but also in vitrification procedures to reduce chilling injury to the cytoskeleton [32]. Beyond its mechanical role, evidence suggests CB can also influence epigenetic modification. In porcine parthenogenetically activated embryos, CB treatment decreased the expression of DNA methyltransferases (DNMT1, DNMT3a, DNMT3b) and promoted the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), potentially contributing to improved developmental competence [33].

Table 1: Core Characteristics of JNJ-7706621 and Cytochalasin B

Feature	JNJ-7706621	Cytochalasin B (CB)
Primary Target	CDK1 & Aurora Kinases	Actin Filaments
Main Molecular Effect	Suppresses CDK1 & MPF activity; Enhances chromosome stability	Inhibits actin polymerization; Relaxes cytoskeleton
Role in SCNT	Post-activation treatment to improve cytoskeletal integrity	Prevents premature cytokinesis post-activation
Reported Secondary Effects	Red DNA damage & blastomere fragmentation [1]	Modifies DNA methylation & histone marks [33]

Quantitative Comparison of Embryonic Development Outcomes

Preimplantation Development Metrics

Rigorous in vitro studies in mouse models provide direct comparative data. When used as a post-activation treatment in SCNT embryos, JNJ-7706621 at a concentration of 10 µM demonstrated significant improvements across all major preimplantation metrics compared to the standard CB treatment.

The blastocyst development rate for the JNJ group was 61.4% ± 4.4%, substantially higher than the 39.9% ± 6.4% observed in the CB group [1] [2]. Beyond the rate of development, the quality of the resulting blastocysts was also superior. JNJ-treated blastocysts exhibited a notably higher total cell number (70.7 ± 2.9 vs. CB: 52.7 ± 3.6), which is a key indicator of embryonic health and developmental potential. This improvement was reflected in both the inner cell mass (ICM) and the trophectoderm (TE) cell lineages [1].

Table 2: In Vitro Preimplantation Development Outcomes in Mouse SCNT Embryos

Development Metric	Cytochalasin B (CB)	JNJ-7706621 (JNJ)
Blastocyst Development Rate	39.9% ± 6.4%	61.4% ± 4.4%
Total Blastocyst Cell Number	52.7 ± 3.6	70.7 ± 2.9
Inner Cell Mass (ICM) Cells	10.4 ± 0.7	15.4 ± 1.1
Trophectoderm (TE) Cells	42.3 ± 3.3	55.3 ± 2.5
Incidence of Apoptotic Cells	Higher	Lower
Abnormal Spindles (1-cell embryo)	Higher	Reduced
Blastomere Fragmentation (2-cell embryo)	Higher	Reduced

Full-Term Developmental Competence

The ultimate test of an embryo's viability is its ability to lead to a live birth. The enhancements in preimplantation quality observed with JNJ-7706621 translated into dramatically improved full-term outcomes. The implantation rate in recipient mice was significantly higher for JNJ-treated SCNT embryos (68.3% ± 4.3%) compared to CB-treated embryos (50.8% ± 3.7%) [1]. Most strikingly, the live birth rate saw a greater than four-fold increase, rising from 2.4% ± 2.4% with CB to 10.9% ± 2.8% with JNJ-7706621 treatment [1] [2]. This underscores JNJ's significant impact on overcoming the major developmental hurdles in cloning.

Experimental Protocols for Key Assays

Standard Post-Activation Treatment Workflow

The following diagram illustrates the core experimental workflow for treating and assessing SCNT embryos, as derived from the cited studies.

Diagram 1: Experimental Workflow for SCNT Embryo Treatment and Assessment

Treatment Application and Culture

Following the activation of reconstructed SCNT embryos, they are immediately subjected to a post-activation treatment for a defined period.

• JNJ-7706621 Protocol: Culture in medium supplemented with 10 µM JNJ-7706621 for 4 hours [1] [3].
• Cytochalasin B Protocol: Culture in medium supplemented with 5 µg/mL CB for 4 hours [1]. After the treatment period, embryos are washed and transferred to a standard culture medium (e.g., PZM-3 for porcine embryos) and maintained under appropriate conditions (e.g., 38.5°C, 5% COâ‚‚) until the blastocyst stage [3] [34].

Key Quality Assessment Methodologies

Researchers employ several assays to quantify the developmental improvements detailed in Section 3.

• Immunofluorescence Staining for Cytoskeleton & DNA Damage: Embryos are fixed and stained with specific antibodies or dyes to visualize F-actin, tubulin (for spindle morphology), and DNA. This allows for the quantification of aberrant cytoskeletal structures and DNA damage in blastomeres, where JNJ treatment shows a significant reduction in these abnormalities [1].
• TUNEL Assay for Apoptosis: The Terminal Deoxynucleotidyl Transferase-mediated dUTP Nick-End Labelling (TUNEL) assay is used to detect fragmented DNA, a hallmark of apoptotic cells. This assay quantitatively shows the lower incidence of apoptosis in blastocysts derived from JNJ-7706621 treated embryos compared to CB [1] [34].
• Cell Number Counting in Blastocysts: Differential staining of the inner cell mass (ICM) and trophectoderm (TE) allows for precise counting of cell numbers in each lineage. This is a critical metric for assessing blastocyst quality, with JNJ-treated embryos showing superior cell numbers [1].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagent Solutions for SCNT Embryo Research

Research Reagent / Material	Primary Function in Protocol
JNJ-7706621	Small molecule inhibitor used in post-activation treatment to enhance cytoskeletal integrity and chromosome stability by targeting CDK1 and Aurora kinases.
Cytochalasin B (CB)	Actin polymerization inhibitor used in post-activation treatment to prevent premature cytokinesis; also used as a cytoskeletal stabilizer in oocyte vitrification.
PZM-3 Culture Medium	A common defined sequential culture medium used for the in vitro development of porcine and other mammalian embryos to the blastocyst stage.
Electro Cell Manipulator	Equipment used for electrical stimulation to activate oocytes after SCNT or parthenogenetic activation.
Anti-Tubulin Antibody	Antibody used in immunofluorescence staining to visualize spindle microtubule structure and assess its normality.
Phalloidin Probe	A high-affinity fluorescent probe used to stain F-actin, enabling the visualization and assessment of microfilament organization in embryos.
TUNEL Assay Kit	A kit containing reagents for labeling DNA strand breaks, allowing for the detection and quantification of apoptotic cells within an embryo.
Carbaryl	Carbaryl | Cholinesterase Inhibitor for Research

The comparative data from rigorous in vitro and in vivo studies indicate a clear trajectory for the future of SCNT embryo research. While cytochalasin B has served as a useful tool, particularly for its cytoskeletal-relaxing properties, the dual-kinase inhibitor JNJ-7706621 offers a more sophisticated, mechanism-driven approach. By directly targeting the core regulators of the cell cycle and chromosome segregation, JNJ-7706621 proactively addresses key sources of developmental failure in cloned embryos. The quantitative evidence across all key metrics—from enhanced cleavage dynamics and reduced DNA damage to superior blastocyst quality and a dramatic increase in live birth rates—suggests that JNJ-7706621 represents a significant advance over traditional CB protocols. For researchers aiming to optimize SCNT efficiency, adopting JNJ-7706621 as a post-activation treatment appears to be a highly promising strategy worthy of further investigation and validation across additional species.

Solving Common SCNT Pitfalls: From Embryo Fragmentation to Epigenetic Barriers

Addressing Blastomere Fragmentation and DNA Damage

Somatic cell nuclear transfer (SCNT) is a pivotal technology in developmental biology, regenerative medicine, and transgenic animal production. However, its widespread application remains constrained by persistently low efficiency, primarily attributable to two interconnected cellular phenomena: blastomere fragmentation and DNA damage. These deficiencies manifest prominently during early embryonic development, leading to arrested development and compromised viability. The selection of cytoskeletal inhibitors and cell cycle regulators during the post-activation phase represents a critical determinant of SCNT success, influencing both structural integrity and genetic stability.

Within this context, scientific investigation has increasingly focused on comparing conventional and novel molecular interventions. Cytochalasin B (CB), a traditional cytoskeletal inhibitor widely used in SCNT protocols to prevent premature chromosome separation, has demonstrated suboptimal performance associated with aberrant actin filament organization and increased fragmentation. Recently, JNJ-7706621 (JNJ), a specific inhibitor of cyclin-dependent kinase 1 (CDK1) and aurora kinases, has emerged as a promising alternative with demonstrated efficacy in enhancing embryonic development. This comprehensive analysis objectively compares these two compounds, evaluating their respective capacities to mitigate blastomere fragmentation and DNA damage while promoting developmental competence in SCNT embryos through systematic examination of experimental data and mechanistic insights.

Comparative Compound Profiles

Table 1: Fundamental Characteristics of Cytochalasin B and JNJ-7706621

Characteristic	Cytochalasin B	JNJ-7706621
Primary Mechanism	Inhibits actin polymerization by capping filament ends [16]	Dual-specific inhibitor of CDK1 and Aurora kinases [1] [3]
Primary Application in SCNT	Prevents pseudo-polar body extrusion post-activation [16]	Promotes proper cell cycle progression and chromosomal segregation [1]
Key Molecular Targets	Actin filaments [16]	CDK1, Aurora kinases A/B [1] [3]
Reported Concentrations	5-7.5 μg/mL [1] [16]	10 μM [1] [3]
Treatment Duration	4 hours [3]	4 hours [3]

Quantitative Performance Comparison

Embryonic Development Outcomes

Rigorous comparative studies in mouse models have yielded substantial quantitative evidence demonstrating the superior efficacy of JNJ-7706621 over cytochalasin B across multiple developmental parameters.

Table 2: Developmental Outcomes of SCNT Embryos Treated with Cytochalasin B vs. JNJ-7706621

Developmental Parameter	Cytochalasin B	JNJ-7706621	Improvement
Blastocyst Formation Rate	39.9% ± 6.4 [1]	61.4% ± 4.4 [1]	+21.5%
Total Blastocyst Cell Count	52.7 ± 3.6 [1]	70.7 ± 2.9 [1]	+18.0 cells
Inner Cell Mass Cells	10.4 ± 0.7 [1]	15.4 ± 1.1 [1]	+5.0 cells
Trophectoderm Cells	42.3 ± 3.3 [1]	55.3 ± 2.5 [1]	+13.0 cells
Implantation Rate	50.8% ± 3.7 [1]	68.3% ± 4.3 [1]	+17.5%
Live Birth Rate	2.4% ± 2.4 [1]	10.9% ± 2.8 [1]	+8.5%

In porcine models, similar enhancement trends were observed. JNJ-7706621 treatment significantly improved blastocyst formation rates in both parthenogenetically activated and SCNT embryos compared to cytochalasin B treatment [3]. This cross-species consistency strengthens the evidence for JNJ's superior performance in supporting embryonic development.

Cellular Integrity and DNA Damage Metrics

Beyond developmental rates, cellular and molecular analyses provide crucial insights into the structural and genetic integrity of embryos treated with these compounds.

Table 3: Cellular and Molecular Integrity Indicators

Parameter	Cytochalasin B	JNJ-7706621	Biological Significance
Apoptotic Cells	Higher incidence [1]	Significant decrease [1]	Enhanced embryo viability
Aberrant F-actin	Prominent [1]	Significantly reduced [1]	Improved cytoskeletal organization
Abnormal Spindles	Higher frequency [1]	Markedly reduced [1]	Proper chromosome segregation
Blastomere Fragmentation	Increased [1]	Substantially decreased [1]	Enhanced structural integrity
DNA Damage	Evident in 2-cell embryos [1]	Significantly reduced [1]	Improved genomic stability

The reduction in blastomere fragmentation with JNJ treatment is particularly significant. Embryo fragmentation involves the presence of membrane-bound cytoplasmic extrusions in the perivitelline space, which can contain entire organelles, chromosomes, or nuclear fragments [35]. These fragments originate through various mechanisms, including apoptotic cell death, membrane compartmentalization of altered DNA, cytoskeletal disorders, and vesicle formation [35]. By reducing fragmentation, JNJ-7706621 promotes healthier embryonic development.

Experimental Protocols and Methodologies

Standardized Treatment Procedures

The experimental protocols for comparing these compounds typically involve specific treatment windows and conditions:

JNJ-7706621 Treatment Protocol:

• Optimal Concentration: 10 μM [1] [3]
• Treatment Initiation: Immediately after artificial activation of reconstructed SCNT embryos [1]
• Duration: 4 hours of exposure in culture medium [3]
• Temperature: Standard embryo culture conditions (37°C for mouse models) [1]

Cytochalasin B Treatment Protocol:

• Concentration: 5 μg/mL (mouse models) [1]; 7.5 μg/mL (porcine models) [16]
• Treatment Window: Applied during post-activation culture [1]
• Duration: Typically 4 hours [3]
• Application: Included in the culture medium following electrical or chemical activation [16]

Assessment Methodologies

Comprehensive evaluation of treatment effects incorporates multiple analytical approaches:

• Developmental Staging: Embryos are cultured in vitro and assessed daily for cleavage rates, blastocyst formation, and expansion status [1]
• Immunofluorescence Staining: Embryos are fixed and stained for cytoskeletal components (α-tubulin, F-actin), DNA damage markers (γH2A.X), and apoptotic markers [1] [36]
• Cell Counting: Differential staining of inner cell mass (ICM) and trophectoderm (TE) cells using specific markers [1]
• Gene Expression Analysis: Quantitative PCR for DNA damage repair pathway genes (HR and NHEJ) [37] [36]
• In Vivo Development Assessment: Embryo transfer to synchronized recipients followed by monitoring of implantation and live birth rates [1]

Mechanisms of Action: A Comparative Analysis

Molecular Pathways

The fundamental difference between these compounds lies in their molecular targets and consequent effects on embryonic reprogramming. The diagram below illustrates the key mechanistic pathways through which JNJ-7706621 and cytochalasin B influence SCNT embryo development.

Cytoskeletal and Epigenetic Regulation

Beyond the primary mechanisms illustrated above, each compound exerts distinct effects on cytoskeletal organization and epigenetic regulation:

JNJ-7706621:

• Cell Cycle Regulation: Suppresses CDK1 activity and reduces M-phase-promoting factor (MPF) levels, facilitating proper cell cycle progression after activation [3]
• Kinase Inhibition: Targets Aurora kinases, essential for spindle assembly and chromosome segregation, thereby reducing aneuploidy [1]
• Transcriptional Effects: Promotes global histone acetylation patterns conducive to embryonic reprogramming [1]

Cytochalasin B:

• Cytoskeletal Disruption: Binds to actin filament ends, preventing polymerization and leading to non-uniform cortical F-actin distribution [16]
• Limited Reprogramming Effects: Does not directly address epigenetic barriers to reprogramming, potentially explaining lower developmental competence [16]
• Species-Specific Variability: Shows differential efficacy across species, with more pronounced fragmentation in porcine models compared to cytochalasin D [16]

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Reagents for SCNT Embryo Research

Reagent Category	Specific Examples	Research Application	Functional Role
Cytoskeletal Inhibitors	Cytochalasin B, Cytochalasin D [16]	Prevents pseudo-polar body extrusion	Actin filament disruption to retain diploid complement
Cell Cycle Regulators	JNJ-7706621 [1] [3]	Post-activation treatment	CDK1 and Aurora kinase inhibition for proper cell cycle progression
HDAC Inhibitors	Trichostatin A, Scriptaid [37] [36]	Epigenetic remodeling	Enhanced DNA damage repair through histone acetylation
Antioxidants	Melatonin [36]	Oxidative stress reduction	DNA damage prevention via free radical scavenging
DNA Damage Markers	γH2A.X antibody [37] [36]	DNA damage assessment	Immunofluorescence detection of double-strand breaks
Apoptosis Detectors	Cleaved caspase-3 antibodies [38]	Apoptosis quantification	Identification of apoptotic activation in blastomeres
Pluripotency Markers	SOX2 antibodies [36]	Embryo quality assessment	Evaluation of inner cell mass development potential

Discussion and Research Implications

Integrated Interpretation of Findings

The consolidated evidence strongly indicates that JNJ-7706621 surpasses cytochalasin B as a strategic intervention for addressing blastomere fragmentation and DNA damage in SCNT embryos. The mechanistic superiority stems from JNJ's multitargeted approach: while cytochalasin B merely addresses the structural aspect of cytokinesis prevention, JNJ-7706621 simultaneously coordinates cell cycle regulation, chromosomal segregation, and cytoskeletal integrity. This comprehensive activity results in substantially improved developmental outcomes, particularly evidenced by the dramatic increase in live birth rates from 2.4% with CB to 10.9% with JNJ treatment [1].

The reduction in DNA damage with JNJ treatment represents a particularly significant advantage. DNA damage in SCNT embryos originates from multiple sources, including oxidative stress [36], incomplete reprogramming [37], and mechanical manipulation during nuclear transfer. While antioxidants like melatonin can mitigate oxidative damage [36] and HDAC inhibitors like scriptaid enhance DNA repair mechanisms [37], JNJ-7706621 appears to preemptively prevent damage through proper chromosome segregation rather than merely facilitating repair.

Research Applications and Future Directions

For researchers designing SCNT experiments, these findings suggest that JNJ-7706621 represents a superior alternative to cytochalasin B for post-activation treatment, particularly in studies where blastomere fragmentation, chromosomal stability, and developmental competence are critical endpoints. The consistent efficacy across mouse [1] and porcine [3] models indicates potentially broad applicability across mammalian species.

Future research directions should focus on:

• Combination Therapies: Investigating synergistic effects of JNJ-7706621 with epigenetic modifiers like Kdm4d/Kdm5b [39] or HDAC inhibitors [37]
• Mechanistic Elucidation: Further exploration of JNJ's effects on specific DNA damage repair pathways (HR and NHEJ) in early embryos
• Protocol Optimization: Determining species-specific optimal concentrations and treatment windows for maximal efficacy
• Long-Term Outcomes: Assessing health and viability of offspring produced through JNJ-7706621-assisted SCNT beyond birth

In conclusion, while cytochalasin B has served as a conventional mainstay in SCNT protocols, the emerging evidence positions JNJ-7706621 as a transformative alternative that directly addresses the interconnected challenges of blastomere fragmentation and DNA damage. Its multitargeted mechanism and demonstrated efficacy across multiple species make it a valuable tool for advancing somatic cell nuclear transfer efficiency and reliability.

Correcting Aberrant Spindle Formation and Chromosome Instability

Somatic Cell Nuclear Transfer (SCNT), or cloning, holds tremendous promise for regenerative medicine, assisted reproduction, and species conservation. However, its utility remains constrained by persistently low success rates, primarily stemming from incomplete cellular reprogramming and structural defects in early embryos. A critical barrier to SCNT efficiency is chromosomal instability (CIN), often initiated by aberrant spindle formation and improper chromosome segregation during the first mitotic divisions [40] [41].

The post-activation protocol is a pivotal stage where chemical treatments are applied to stabilize the reconstructed embryo. For years, cytochalasin B (CB), an actin polymerization inhibitor, has been a standard reagent in this phase, primarily to prevent extrusion of the donor chromatin. Nevertheless, developmental outcomes remain suboptimal. Recently, JNJ-7706621 (JNJ), a small-molecule inhibitor targeting cyclin-dependent kinase 1 (CDK1) and Aurora kinases, has emerged as a promising alternative, demonstrating significant potential to correct spindle and chromosome defects intrinsic to SCNT embryos [3] [1].

This guide provides an objective, data-driven comparison of JNJ-7706621 versus the conventional cytochalasin B, focusing on their efficacy in correcting spindle formation and ensuring chromosome stability during SCNT embryo development.

Comparative Performance Data

The comparative efficacy of JNJ-7706621 and cytochalasin B has been evaluated across multiple species and developmental endpoints. The data below summarize key quantitative findings from published studies.

Table 1: In Vitro Preimplantation Development of PA and SCNT Embryos

Treatment	Embryo Type	Species	Blastocyst Rate (%)	Total Cell Number	Apoptotic Cells	Reference
JNJ-7706621 (10 μM)	Parthenogenetic	Porcine	Significantly Higher*	N/R	N/R	[3]
Cytochalasin B (5 μg/mL)	Parthenogenetic	Porcine	Baseline	N/R	N/R	[3]
JNJ-7706621 (10 μM)	SCNT	Porcine	Significantly Higher*	N/R	N/R	[3]
Cytochalasin B (5 μg/mL)	SCNT	Porcine	Baseline	N/R	N/R	[3]
JNJ-7706621 (10 μM)	Parthenogenetic	Mouse	High Competency	Increased*	Decreased*	[1]
Cytochalasin B (5 μg/mL)	Parthenogenetic	Mouse	High Competency	Baseline	Baseline	[1]
JNJ-7706621 (10 μM)	SCNT	Mouse	61.4% ± 4.4*	70.7 ± 2.9*	N/R	[1]
Cytochalasin B (5 μg/mL)	SCNT	Mouse	39.9% ± 6.4	52.7 ± 3.6	N/R	[1]

N/R: Not Reported in the context of the comparison; *Statistically significant difference (P<0.05) compared to CB treatment.

Table 2: In Vivo Full-Term Development of SCNT Mouse Embryos

Treatment	Implantation Rate (%)	Live Birth Rate (%)	Inner Cell Mass Cells	Trophectoderm Cells	Reference
JNJ-7706621 (10 μM)	68.3% ± 4.3*	10.9% ± 2.8*	15.4 ± 1.1*	55.3 ± 2.5*	[1]
Cytochalasin B (5 μg/mL)	50.8% ± 3.7	2.4% ± 2.4	10.4 ± 0.7	42.3 ± 3.3	[1]

Statistically significant difference (P<0.05) compared to CB treatment.

Underlying Mechanisms: Molecular Pathways and Actions

The superior performance of JNJ-7706621 is rooted in its targeted action on the core biochemical regulators of cell division, directly correcting the cellular flaws prevalent in SCNT embryos.

JNJ-7706621 Mechanism: Dual-Target Inhibition

JNJ-7706621 functions primarily as an ATP-competitive inhibitor of CDK1 and Aurora kinases [1]. In SCNT embryos, this dual action translates into a coordinated rescue of mitotic fidelity:

• Suppression of CDK1 and MPF Activity: Treatment with 10μM JNJ for 4 hours significantly reduces M-phase-promoting factor (MPF) activity, a key driver of the oocyte's metaphase-II arrest. This suppression facilitates a more complete and stable nuclear remodeling after transfer [3].
• Promotion of Proper Kinectochore-Microtubule Attachments: By inhibiting Aurora kinases, JNJ-7706621 corrects a critical deficiency in SCNT embryos. Aurora B is essential for destabilizing erroneous microtubule-kinetochore attachments, thereby preventing merotelic attachments (where a single kinetochore attaches to microtubules from both spindle poles)—a common source of anaphase lagging chromosomes and micronuclei [40] [42]. This action directly reduces aberrant spindles and chromosome mis-segregation [1].

The following diagram illustrates how JNJ-7706621 targets key molecular pathways to correct defects in SCNT embryos.

Cytochalasin B Mechanism: Cytoskeletal Inhibition

Cytochalasin B's primary role is the inhibition of actin polymerization by capping the fast-growing end of actin filaments [1]. In SCNT protocols:

• Prevention of Cytokinesis: Its main function is to enforce a single pseudo-pronucleus by physically blocking polar body extrusion and cytokinesis after oocyte activation.
• Lack of Direct Mitotic Correction: While effective for its intended purpose, CB does not directly address the underlying chromosome spacing defects, spindle assembly errors, or deficiencies in spindle protein recruitment (such as clathrin heavy chain or aurora B) that are hallmarks of SCNT embryos [40]. It is a mechanical stopgap that does not enhance the intrinsic reprogramming of the donor nucleus.

Detailed Experimental Protocols

To ensure reproducibility and provide a clear framework for the comparative data, the key methodologies from the cited studies are outlined below.

Protocol 1: Post-Activation Treatment for Porcine & Mouse Embryos

This protocol is adapted from studies by Guo et al. (2018) and the Theriogenology (2025) article, which compared JNJ-7706621 and cytochalasin B directly [3] [1].

• SCNT Embryo Production: Perform standard SCNT using enucleated MII oocytes and donor somatic cells (e.g., cumulus cells or fibroblasts).
• Artificial Activation: Activate reconstructed oocytes using appropriate methods, such as calcium ionophore or electrical stimulation.
• Post-Activation Treatment (Immediately after activation):
  • Experimental Group: Culture embryos in medium supplemented with 10μM JNJ-7706621 for 4 hours.
  • Control Group: Culture embryos in medium supplemented with 5 μg/mL Cytochalasin B for 4 hours.
• Embryo Washing and Culture: After treatment, wash embryos thoroughly to remove the chemicals and culture them in a standard embryo culture medium (e.g., CZB or PZM-5) under optimal conditions (5% COâ‚‚, 95% air, 38.5°C).
• Outcome Assessment: Assess blastocyst formation rates at Day 7 (porcine) or Day 4 (mouse). Perform differential staining for inner cell mass (ICM) and trophectoderm (TE) cell counts, and TUNEL assay for apoptosis.

Protocol 2: Analyzing Chromosome Segregation and Spindle Integrity

This protocol is based on cytogenetic analyses performed to elucidate the mechanisms of CIN in SCNT embryos [1] [41].

• Embryo Fixation and Staining: At specific timepoints (e.g., first mitosis), fix embryos and perform immunocytochemistry.
  • Microtubules: Stain with anti-α-tubulin antibody.
  • Chromosomes/DNA: Stain with DAPI or Hoechst.
  • Kinetochores: Stain with an antibody against CREST antigen.
  • DNA Damage: Stain with an antibody against γH2AX.
• Confocal Microscopy and Image Analysis: Acquire high-resolution z-stack images using a confocal microscope. Analyze images for:
  • Spindle Morphology: Presence of bipolar, monopolar, or multipolar spindles.
  • Chromosome Congression: Alignment of chromosomes at the metaphase plate.
  • Segregation Errors: Frequency of lagging chromosomes (merotelic attachments), chromosome bridges (pre-mitotic replication defects), and acentric fragments in anaphase/telophase [43] [41].
  • Micronuclei Formation: Presence of micronuclei in subsequent interphase.

The experimental workflow for investigating spindle and chromosome defects is summarized below.

The Scientist's Toolkit: Key Research Reagents

Table 3: Essential Reagents for SCNT Embryo Research on Spindle and Chromosome Stability

Reagent/Solution	Category	Key Function in Research	Example Application
JNJ-7706621	Small Molecule Inhibitor	Dual-specificity inhibitor of CDK1 and Aurora kinases; used to suppress MPF activity and correct erroneous kinetochore-microtubule attachments.	Post-activation treatment to improve spindle integrity and reduce aneuploidy in SCNT embryos. [3] [1]
Cytochalasin B	Cytoskeletal Inhibitor	Inhibits actin polymerization; used to prevent cytokinesis and polar body extrusion after oocyte activation.	Standard control treatment in post-activation protocols to ensure diploidy. [3] [1]
Anti-α-Tubulin Antibody	Immunofluorescence Reagent	Labels microtubule networks; essential for visualizing spindle structure, morphology, and bipolarity.	Assessment of spindle assembly and defects in fixed SCNT embryos. [1] [41]
CREST Antiserum	Immunofluorescence Reagent	Labels kinetochores; allows for quantification of kinetochore number and attachment to spindle microtubules.	Identification of merotelic attachments and chromosome mis-congression. [41] [42]
Anti-γH2AX Antibody	Immunofluorescence Reagent	Marker for DNA double-strand breaks; indicates replication stress and DNA damage in the nucleus.	Evaluation of DNA damage resulting from chromosome segregation errors and mitotic defects. [41]
Nocodazole	Microtubule Depolymerizer	Arrests cells in prometaphase by disrupting microtubule polymerization; used for synchronizing donor cells.	Preparation of mitotic donor nuclei for nuclear transfer. [41]

The comparative data from multiple independent studies consistently demonstrate that JNJ-7706621 outperforms the traditional reagent cytochalasin B as a post-activation treatment for SCNT embryos. JNJ-7706621's superiority is not merely incremental but fundamental, shifting the approach from passive containment (preventing cytokinesis with CB) to active correction (resolving spindle and chromosome defects). By targeting the core regulators of mitosis, JNJ-7706621 directly mitigates the chromosomal instability that has long plagued SCNT efficiency, leading to significantly improved preimplantation development and, crucially, a higher live birth rate. For researchers aiming to optimize SCNT protocols and investigate the mechanisms of mitotic fidelity in reprogrammed cells, JNJ-7706621 represents a compelling and evidence-based advanced reagent choice.

Somatic Cell Nuclear Transfer (SCNT) remains a pivotal technique in reproductive biotechnology, livestock cloning, and biomedical research, yet its application is severely hampered by consistently low efficiency rates of just 1-5% [44]. The developmental failure of cloned embryos stems from two primary categories of obstacles: technical limitations in nuclear reprogramming and profound biological barriers rooted in epigenetic irregularities. This review examines a novel, synergistic approach that combines the cell cycle synchronization capabilities of the cyclin-dependent kinase (CDK) inhibitor JNJ-7706621 with emerging epigenetic modulation strategies to potentially overcome these persistent challenges.

The broader thesis framing this comparison centers on the mechanistic superiority of JNJ-7706621 over the conventional cytoskeletal-disrupting agent cytochalasin B for enhancing SCNT embryo development. While cytochalasin B has historically been used for cytoskeletal stabilization during SCNT procedures, its non-specific mechanism fails to address the fundamental cell cycle and epigenetic barriers to successful nuclear reprogramming [3]. Emerging evidence suggests that targeted CDK inhibition via JNJ-7706621 not only improves initial embryonic development but may also establish a more permissive epigenetic landscape for subsequent modulatory interventions.

Comparative Performance Analysis: JNJ-7706621 vs. Cytochalasin B

Direct Experimental Comparison in Porcine Models

Rigorous comparative studies have quantified the developmental advantages of JNJ-7706621 over cytochalasin B in porcine SCNT embryos. The foundational research by Guo et al. demonstrated that a specific treatment protocol using 10µM JNJ-7706621 for 4 hours significantly improved blastocyst formation rates compared to the standard cytochalasin B treatment (5µg/mL for 4 hours) [3].

Table 1: Direct Comparison of JNJ-7706621 vs. Cytochalasin B on Porcine SCNT Embryo Development

Treatment Parameter	JNJ-7706621	Cytochalasin B	Statistical Significance
Blastocyst Rate (PA)	Significantly higher	Lower	P < 0.05
Blastocyst Rate (SCNT)	Significantly higher	Lower	P < 0.05
MPF Level	Significantly reduced	Higher	P < 0.05
CDK1 Tyr15 Phosphorylation	Significantly elevated	Lower	P < 0.05
CDK1 Thr161 Phosphorylation	Significantly lower	Higher	P < 0.05
Proposed Mechanism	Suppresses CDK1 activity, reduces MPF	Cytoskeletal disruption	N/A

Molecular Mechanisms Underlying Developmental Improvements

The superior performance of JNJ-7706621 stems from its targeted effect on fundamental cell cycle regulators. Treatment with JNJ-7706621 specifically suppressed M-phase-promoting factor (MPF) activity, a crucial regulator of meiotic and mitotic transitions [3]. Simultaneously, it elevated Tyr15 phosphorylation while reducing Thr161 phosphorylation of the cyclin p34cdc2 (CDK1) complex, creating a biochemical environment more conducive to proper nuclear reprogramming [3]. This targeted cell cycle manipulation contrasts sharply with cytochalasin B's mechanism, which primarily disrupts actin polymerization without directly addressing cell cycle synchronization barriers.

Experimental Protocols and Methodological Approaches

Standardized JNJ-7706621 Treatment Protocol

The optimized protocol for JNJ-7706621 application in SCNT embryos involves specific parameters validated through empirical testing:

• Compound Preparation: JNJ-7706621 is dissolved in DMSO to create a stock solution, then diluted in the appropriate embryo culture medium to achieve a final concentration of 10µM [3].

• Treatment Timing: Application occurs immediately after oocyte activation or nuclear transfer procedures [3].

• Exposure Duration: A 4-hour treatment window has demonstrated optimal results for both parthenogenetic and SCNT-derived embryos [3].

• Post-Treatment Processing: Following treatment, embryos are thoroughly washed to remove the compound and transferred to standard culture conditions for continued development [3].

Complementary Oocyte Handling Techniques

Recent advancements in oocyte handling protocols demonstrate compatibility with JNJ-7706621 treatment. The delayed maturation technique, which involves holding bovine oocytes for 20-24 hours in simple medium prior to conventional maturation, maintains developmental competence while offering operational flexibility [45]. This approach enables better synchronization of donor cell and recipient oocyte cell cycles, potentially enhancing the effectiveness of subsequent JNJ-7706621 treatment.

Signaling Pathways and Molecular Interactions

The molecular pathways targeted by JNJ-7706621 intersect critically with epigenetic reprogramming barriers. The following diagram illustrates key signaling relationships and intervention points:

Diagram 1: Molecular targeting of JNJ-7706621 versus cytochalasin B in SCNT embryo development. JNJ-7706621 directly modulates CDK1 and MPF activity, influencing epigenetic barriers like H3K9me3 that impede reprogramming.

Epigenetic Barriers and Modulatory Opportunities

Key Epigenetic Obstacles in SCNT Embryos

Incomplete epigenetic reprogramming represents the most significant biological barrier to SCNT efficiency. Several specific epigenetic anomalies have been identified:

• H3K9me3 Hypermethylation: This repressive histone modification creates reprogramming-resistant regions (RRRs) that block proper zygotic genome activation (ZGA), particularly at the 2-cell stage in mouse embryos [44]. These regions maintain somatic memory and prevent expression of developmentally critical genes.

• Aberrant DNA Methylation Patterns: SCNT embryos often retain somatic DNA methylation signatures that disrupt normal embryonic gene expression programs, leading to impaired preimplantation and postimplantation development [44].

• X-Chromosome Inactivation Defects: Abnormal regulation of Xist and other X-chromosome inactivation mechanisms frequently occurs in cloned embryos, contributing to developmental failure, particularly in female embryos [46] [44].

Strategic Combination with Epigenetic Modulators

The cell cycle synchronization achieved through JNJ-7706621 treatment creates a strategic opportunity for combination with targeted epigenetic modulators. By first optimizing the cell cycle environment, the subsequent application of epigenetic modifiers may achieve more comprehensive reprogramming:

Table 2: Potential Epigenetic Modulators for Combination Strategies with JNJ-7706621

Epigenetic Target	Exemplary Modulators	Proposed Mechanism	Potential Synergy with JNJ-7706621
H3K9me3	UNC0642, Chaetocin	Inhibits H3K9 methyltransferases	Reduced reprogramming barriers during ZGA
DNA Methylation	5-Aza-2'-deoxycytidine	Inhibits DNA methyltransferases	Enhanced epigenetic plasticity
Histone Acetylation	Trichostatin A, Scriptaid	Inhibits histone deacetylases	More open chromatin configuration
X-Chromosome	Xist RNAi	Corrects X-inactivation defects	Improved female embryo development

Advanced SCNT Workflow Integrating Combined Strategies

The integration of JNJ-7706621 with complementary techniques and potential epigenetic modulators creates an optimized SCNT workflow:

Diagram 2: Integrated SCNT workflow combining delayed oocyte maturation, JNJ-7706621 treatment, and optional epigenetic modulation to enhance blastocyst development.

Table 3: Key Research Reagents for SCNT Enhancement Studies

Reagent/Category	Specific Examples	Function/Application
CDK Inhibitors	JNJ-7706621, R547, AZD5438	Cell cycle synchronization, MPF regulation
Cytoskeletal Agents	Cytochalasin B	Conventional cytoskeletal stabilization
Epigenetic Modulators	Trichostatin A, UNC0642, 5-Aza-dC	Enhanced epigenetic reprogramming
Oocyte Holding Media	Commercial embryo holding media	Delayed maturation protocols
Donor Cell Types	Fibroblasts, induced pluripotent stem cells (iPSCs)	Nuclear transfer sources
Activation Agents	Cycloheximide, ionomycin	Artificial oocyte activation

The strategic combination of JNJ-7706621's cell cycle regulation with targeted epigenetic modulation represents a promising frontier in SCNT optimization. The documented superiority of JNJ-7706621 over cytochalasin B in enhancing blastocyst development establishes a foundation for more sophisticated reprogramming strategies. Future research should prioritize determining optimal sequencing of these interventions, identifying specific epigenetic modifiers with the greatest synergistic potential, and validating these approaches across multiple species. The integration of complementary techniques such as delayed oocyte maturation and the use of induced pluripotent stem cells as nuclear donors may further enhance the efficacy of this combined approach [45]. As our understanding of epigenetic barriers deepens, the precision with which we can design these combinatorial strategies will undoubtedly improve, potentially unlocking new levels of SCNT efficiency for both basic research and applied biotechnology.

Optimizing Post-Activation Treatments to Overcome Developmental Arrest

Somatic cell nuclear transfer (SCNT) is a pivotal technique in reproductive biotechnology and regenerative medicine, yet its application is consistently hampered by a significant challenge: developmental arrest. A predominant cause of this arrest is the compromised cytoskeletal and chromosomal integrity of reconstructed embryos immediately following activation. The choice of post-activation treatment is therefore critical for successful outcomes. Within this context, the conventional agent cytochalasin B (CB) has been the standard for decades, primarily functioning to prevent premature cytokinesis. However, emerging research highlights the superior efficacy of JNJ-7706621, a dual-specific inhibitor of cyclin-dependent kinase 1 (CDK1) and Aurora kinases, in not only supporting but actively enhancing embryonic development. This guide provides a direct, data-driven comparison of these two compounds for researchers aiming to optimize SCNT protocols.

Experimental Protocols & Workflow

To objectively assess the performance of JNJ-7706621 against cytochalasin B, the following core experimental workflow, derived from key studies, should be implemented.

Embryo Reconstruction and Treatment

• SCNT Protocol: Perform standard somatic cell nuclear transfer using enucleated metaphase II (MII) oocytes and donor somatic cells (e.g., fibroblasts arrested in G0/G1 phase) [47].
• Parthenogenetic Activation (PA) Control: Include a cohort of parthenogenetically activated embryos to isolate the effects of the treatments from the complexities of nuclear transfer [2] [1].
• Post-Activation Treatment:
  • Control Group: Culture reconstructed embryos in medium supplemented with 5 μg/mL Cytochalasin B (CB).
  • Experimental Group: Culture reconstructed embryos in medium supplemented with 10 μM JNJ-7706621.
  • The treatment is applied post-activation for a defined culture period [2] [1].

Developmental and Quality Assessment

• Developmental Competence: Monitor and record the rates of cleavage, blastocyst formation, implantation, and live birth.
• Blastocyst Quality Analysis:
  • Total Cell Count: Perform differential staining to quantify the number of cells in the Inner Cell Mass (ICM) and Trophectoderm (TE).
  • Apoptosis Assay: Use a TUNEL assay or similar to detect apoptotic cells within the blastocyst.
• Cytoskeletal and Chromosomal Integrity:
  • Immunofluorescence: Stain one-cell and two-cell embryos for F-actin and α-tubulin to visualize actin filaments and spindle morphology.
  • DNA Damage Assessment: Use markers like γH2AX to evaluate DNA damage in two-cell embryos [2] [1].

The following diagram illustrates the logical sequence of this experimental workflow:

Quantitative Performance Comparison

The efficacy of JNJ-7706621 and Cytochalasin B is directly compared across multiple critical developmental parameters in the tables below. All data are presented as mean ± standard error and are sourced from a controlled mouse SCNT study [2] [1].

Table 1: Pre-implantation Development and Blastocyst Quality in Mouse SCNT Embryos

Developmental Parameter	Cytochalasin B (CB)	JNJ-7706621 (JNJ)	Reference
Blastocyst Development Rate	39.9% ± 6.4	61.4% ± 4.4	[2] [1]
Total Blastocyst Cell Number	52.7 ± 3.6	70.7 ± 2.9	[2] [1]
Inner Cell Mass (ICM) Cells	10.4 ± 0.7	15.4 ± 1.1	[2] [1]
Trophectoderm (TE) Cells	42.3 ± 3.3	55.3 ± 2.5	[2] [1]
Incidence of Apoptotic Cells	Higher	Significantly Reduced	[2] [1]

Table 2: Post-Implantation Outcomes and Cellular Integrity in Mouse SCNT Embryos

Outcome Parameter	Cytochalasin B (CB)	JNJ-7706621 (JNJ)	Reference
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	[2] [1]
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	[2] [1]
Abnormal Spindle Morphology	Higher	Significantly Reduced	[2] [1]
Blastomere Fragmentation & DNA Damage	Higher	Significantly Reduced	[2] [1]
Aberrant F-actin/Tubulin	Higher	Significantly Reduced	[2] [1]

Mechanism of Action: A Comparative Analysis

The superior performance of JNJ-7706621 is rooted in its fundamental mechanism of action, which addresses the causes of developmental arrest more comprehensively than CB.

• Cytochalasin B (CB): This agent operates through a relatively simple mechanism. It is a fungal metabolite that inhibits actin polymerization by capping the growing plus end of actin filaments. In SCNT, its primary role is mechanical—it prevents the extrusion of a pseudo-polar body or premature cytokinesis, thereby helping to maintain diploidy. However, it does not directly address chromosomal mis-segregation or DNA damage resulting from erroneous spindle assembly [2].

• JNJ-7706621: This small molecule is a multi-kinase inhibitor. Its primary targets are:

  • CDK1: A master regulator of the cell cycle that governs the G2/M transition and mitotic progression.
  • Aurora Kinases (AURKA/B): Key kinases essential for accurate chromosome segregation, spindle assembly, and cytokinesis [2] [21].

By co-inhibiting these targets, JNJ-7706621 induces a transient mitotic arrest. This provides the embryo with a critical window of time to correct improper kinetochore-microtubule attachments and properly align chromosomes on a bipolar spindle. Consequently, upon release from arrest, the embryo exhibits significantly higher rates of correct chromosome segregation, reduced aneuploidy, and diminished DNA damage, which directly translates to enhanced developmental potential [2] [1].

The following diagram contrasts the mechanistic pathways of these two agents:

The Scientist's Toolkit: Essential Research Reagents

The following table catalogues the key reagents required to implement the described SCNT optimization experiments.

Table 3: Key Research Reagents for SCNT Post-Activation Studies

Reagent / Solution	Function / Application	Example Usage in Protocol
JNJ-7706621	Dual CDK1/Aurora kinase inhibitor; post-activation treatment to improve chromosomal integrity and developmental rates.	Used at 10 μM in culture medium post-activation [2] [1].
Cytochalasin B (CB)	Actin polymerization inhibitor; standard post-activation treatment to prevent cytokinesis.	Used at 5 μg/mL in culture medium post-activation as a control [2] [1].
Antibody: α-Tubulin	Immunofluorescence staining of microtubules to visualize spindle morphology and integrity.	Assess spindle normality in one-cell embryos [2] [1].
Antibody: γH2AX	Immunofluorescence marker for identifying sites of DNA double-strand breaks.	Evaluate DNA damage in two-cell stage SCNT embryos [2].
Cell Death Detection Kit (e.g., TUNEL assay)	Fluorescent labeling of apoptotic cells within embryos.	Quantify apoptosis levels in blastocysts [2] [48].
Differential Staining Kit	Simultaneous staining of Inner Cell Mass (ICM) and Trophectoderm (TE) cells.	Analyze blastocyst quality and cell number composition [2] [1].

The comparative data unequivocally demonstrates that JNJ-7706621 represents a significant advancement over cytochalasin B for overcoming developmental arrest in SCNT embryos. While CB serves a limited mechanical function, JNJ-7706621 actively rescues the embryo by addressing the core issues of chromosomal instability and cytoskeletal defects. The result is a robust improvement across all metrics—from blastocyst quality and cell numbers to the ultimate benchmark of live birth rates. For research focused on enhancing SCNT efficiency, adopting JNJ-7706621 as the next-generation post-activation treatment is a strategically supported choice.

Head-to-Head: Quantifying Superiority in Pre- and Post-Implantation Outcomes

Within the field of assisted reproductive technologies and animal cloning, the efficiency of blastocyst development serves as a critical benchmark for evaluating embryonic health and the success of laboratory protocols. For researchers utilizing somatic cell nuclear transfer (SCNT), the choice of post-activation chemicals is paramount for optimizing outcomes. This comparison guide provides an objective, data-driven analysis of two key agents—JNJ-7706621 and cytochalasin B (CB)—in the context of SCNT embryo development. JNJ-7706621 is a specific inhibitor of cyclin-dependent kinase 1 (CDK1) and aurora kinases [1] [3], while cytochalasin B is an actin polymerization inhibitor commonly used in SCNT protocols [33]. By presenting consolidated experimental data and detailed methodologies, this review aims to equip scientists with the evidence necessary to select the most appropriate reagent for their research on reprogramming and embryonic development.

Statistical Showdown: Quantitative Performance Review

The following tables summarize key experimental data comparing the effects of JNJ-7706621 and cytochalasin B on embryo development across multiple studies and species.

Table 1: Preimplantation Development Metrics in Mouse SCNT Embryos

Development Metric	Cytochalasin B (CB)	JNJ-7706621 (10 μM)	Reference
Blastocyst Development Rate	39.9% ± 6.4	61.4% ± 4.4	[1] [2]
Total Blastocyst Cell Number	52.7 ± 3.6	70.7 ± 2.9	[1] [2]
Inner Cell Mass (ICM) Cells	10.4 ± 0.7	15.4 ± 1.1	[1] [2]
Trophectoderm (TE) Cells	42.3 ± 3.3	55.3 ± 2.5	[1] [2]

Table 2: Full-Term Development and Cellular Quality in Mouse SCNT

Outcome Metric	Cytochalasin B (CB)	JNJ-7706621 (10 μM)	Reference
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	[1] [2]
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	[1] [2]
Apoptotic Cells in Blastocyst	Higher	Significantly Decreased	[1] [2]
Abnormal Spindles / DNA Damage	Present	Significantly Reduced	[1] [2]

Table 3: Performance in Porcine Parthenogenetic (PA) and SCNT Embryos

Embryo Type / Metric	Cytochalasin B (5 μg/mL)	JNJ-7706621 (10 μM)	Reference
PA Blastocyst Rate	Baseline	Significantly Higher	[3]
SCNT Blastocyst Rate	Baseline	Significantly Higher	[3]
MPF Level	Higher	Significantly Lower	[3]
CDK1 (Tyr15 Phosphorylation)	Lower	Significantly Elevated	[3]

Experimental Protocols and Workflows

Standardized SCNT and Treatment Protocol

The following workflow visualizes a generalized SCNT experiment for comparing post-activation treatments, synthesized from the reviewed studies [1] [49] [47].

Key Methodological Details

The core comparative studies involved treating embryos for a defined period (4 hours) immediately following artificial activation [3] [2]. The optimal concentration of JNJ-7706621 was determined through dose-response experiments in parthenogenetically activated (PA) mouse embryos, comparing 1, 10, and 50 μM concentrations against the standard CB (5 μg/mL) control. The 10 μM concentration consistently yielded the highest developmental competence [1] [2].

Outcome assessments were rigorously conducted. Blastocyst development rates were recorded typically on Day 7 for pigs [3] and Day 4 for mice [1]. Quality assessments included total cell counting via immunostaining, apoptosis analysis using TUNEL assays, and evaluation of cytoskeletal integrity through immunolabeling of F-actin and tubulin [1] [2]. For full-term potential, implantation and live birth rates were evaluated by transferring developed blastocysts into surrogate females [1].

Mechanism of Action: Signaling Pathways

The superior performance of JNJ-7706621 is rooted in its targeted mechanism of action, which directly enhances key reprogramming events. The following diagram illustrates the proposed signaling pathway through which JNJ-7706621 improves SCNT outcomes.

In contrast, Cytochalasin B primarily functions as an actin polymerization inhibitor, preventing cytokinesis to allow for the formation of a single reconstructed embryo [33]. While effective for this purpose, its mechanism is less directly involved in correcting the crucial epigenetic and chromosomal irregularities common in SCNT embryos. Research indicates that CB can influence epigenetic marks, such as promoting the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and modulating histone modifications [33]. However, JNJ-7706621's targeted inhibition of CDK1 and Aurora kinases more directly addresses the core issue of chromosome instability and inadequate nuclear reprogramming, which are major bottlenecks in SCNT efficiency [1] [49].

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Reagent Solutions for SCNT Embryo Research

Reagent / Solution	Function in Protocol	Example Usage in Cited Studies
JNJ-7706621	Selective CDK1 & Aurora kinase inhibitor; improves reprogramming by enhancing cytoskeletal and chromosome integrity.	Used at 10 μM for 4h post-activation in mouse/porcine SCNT [1] [3].
Cytochalasin B (CB)	Actin polymerization inhibitor; prevents cytokinesis post-activation to maintain diploidy.	Used at 5 μg/mL for 4h post-activation as a standard control [33] [3].
Oocyte Activation Media	Chemically induces exit from MII arrest; typically contains SrCl₂ for mouse or Ca²⁺ ionophore.	Used post-fusion to initiate embryonic development [1] [47].
Scriptaid / 5-Aza-2'-deoxycytidine	Epigenetic modifiers (HDAC inhibitor/DNA methyltransferase inhibitor); can improve reprogramming.	Combined with CB to further enhance blastocyst development in porcine PA embryos [33].
Lycopene	Potent antioxidant; reduces ROS and improves epigenetic reprogramming/ZGA.	Used at 0.2 μM in porcine embryo culture medium [7].
Embryo Culture Media	Supports in vitro development from zygote to blastocyst; e.g., KSOM, PZM.	Used for extended culture post-treatment to assess blastocyst rates [1] [7].

Discussion and Research Implications

The consolidated data demonstrates a clear trend: post-activation treatment with JNJ-7706621 consistently outperforms cytochalasin B as a single agent across multiple critical metrics, including blastocyst quality, implantation potential, and, most significantly, live birth rates in mouse models [1] [2]. The mechanistic evidence suggests this superiority stems from JNJ-7706621's multi-targeted approach, which not only facilitates proper cell cycle arrest but also actively promotes cytoskeletal integrity and reduces DNA damage [1].

For researchers, the choice of reagent depends on the experimental goals. If the primary objective is the production of high-quality blastocysts for therapeutic cloning or embryonic stem cell derivation, JNJ-7706621 presents a compelling option based on its ability to generate blastocysts with higher cell counts, particularly in the inner cell mass, which gives rise to stem cells [1] [49]. Furthermore, its significant boost in live birth rates makes it highly valuable for reproductive cloning research in animal models [1] [2].

However, the combination of cytochalasin B with other epigenetic modulators like Scriptaid has also shown synergistic benefits for embryonic development [33]. This indicates that optimized CB-based cocktail regimens may still be highly effective and could be a focus for protocol refinement.

Future research should explore the combination of JNJ-7706621's cytoskeletal-stabilizing properties with antioxidants like lycopene, which has been shown to reduce reactive oxygen species and improve epigenetic reprogramming in porcine SCNT embryos [7]. This multi-faceted approach, targeting both structural chromosome integrity and oxidative stress, may represent the next frontier in maximizing SCNT efficiency.

In somatic cell nuclear transfer (SCNT) research, the selection of cytostatic agents is critical for ensuring high-quality embryonic development. This guide objectively compares the performance of JNJ-7706621, a cyclin-dependent kinase and Aurora kinase inhibitor, against the traditionally used cytochalasin B (CB), with a specific focus on cellular quality parameters including inner cell mass (ICM) formation, trophectoderm (TE) development, and apoptosis regulation. The data presented herein, derived from recent peer-reviewed studies, provides a comprehensive analysis of how these compounds influence pre-implantation development and full-term outcomes in SCNT embryos, offering researchers evidence-based insights for protocol optimization.

Comparative Performance Data

The following tables synthesize quantitative experimental data comparing the effects of JNJ-7706621 and cytochalasin B on SCNT embryo development across multiple studies and species.

Table 1: Pre-implantation Development of Mouse SCNT Embryos

Development Parameter	Cytochalasin B (CB)	JNJ-7706621 (10 µM)	Significance
Blastocyst Rate	39.9% ± 6.4	61.4% ± 4.4	P < 0.05 [1] [2]
Total Cell Number	52.7 ± 3.6	70.7 ± 2.9	P < 0.05 [1] [2]
Inner Cell Mass (ICM) Cells	10.4 ± 0.7	15.4 ± 1.1	P < 0.05 [1] [2]
Trophectoderm (TE) Cells	42.3 ± 3.3	55.3 ± 2.5	P < 0.05 [1] [2]
Apoptotic Cell Reduction	Baseline	Significant Decrease	P < 0.05 [1] [2]

Table 2: Post-Implantation and Full-Term Development in Mouse SCNT

Development Parameter	Cytochalasin B (CB)	JNJ-7706621 (10 µM)	Significance
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	P < 0.05 [1] [2]
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	P < 0.05 [1] [2]

Table 3: Porcine SCNT and Parthenogenetic (PA) Embryo Development

Development Parameter	Cytochalasin B (5 µg/mL)	JNJ-7706621 (10 µM)	Significance
PA Blastocyst Rate	Lower than JNJ	Significantly Higher	P < 0.05 [3]
SCNT Blastocyst Rate	Lower than JNJ	Significantly Higher	P < 0.05 [3]

Detailed Experimental Protocols

Treatment and Culture Conditions for Mouse SCNT

The foundational studies comparing JNJ-7706621 and cytochalasin B in mouse cloning utilized the following standardized protocol [1] [2]:

• Oocyte Collection and Enucleation: Metaphase II (MII) oocytes are collected from superovulated mice. The spindle-chromosome complex is removed in Hepes-buffered CZB medium (HCZB) containing 10 µg/mL cytochalasin B using a piezo-actuated micromanipulator.
• Nuclear Transfer and Fusion: A somatic donor cell (e.g., cumulus cell) is injected into the perivitelline space of the enucleated oocyte. The couplet is fused using an electrical stimulus (e.g., two DC pulses of 34 V for 15 µsec).
• Chemical Activation and Treatment: Post-fusion, reconstructed oocytes are activated in a medium containing 10 mM SrClâ‚‚. It is at this critical juncture that the experimental groups are differentiated:
  • Control Group: Treated with 5 µg/mL cytochalasin B.
  • Experimental Group: Treated with 10 µM JNJ-7706621.
  • The treatment duration is 4-6 hours post-activation.
• In Vitro Culture (IVC): Embryos are washed and subsequently cultured in a sequential medium (e.g., KSOM or G1/G2 media) under conditions of 5% Oâ‚‚, 5% COâ‚‚, and 90% Nâ‚‚ at 37°C for up to 4 days to assess pre-implantation development [50] [17].
• In Vivo Assessment: For full-term development analysis, surgically transferred embryos into pseudopregnant recipients are assessed for implantation sites and live-born pups.

Key Cellular and Molecular Assessments

The superior outcomes attributed to JNJ-7706621 are explained by in-depth cellular quality analyses performed at specific developmental stages:

• Immunofluorescence Staining: Blastocysts are fixed and stained with markers for:
  • ICM and TE: Anti-CDX2 for TE and anti-NANOG or anti-SOX2 for ICM, followed by cell counting to quantify lineage composition [1] [2].
  • Cytoskeletal Integrity: Staining for F-actin (with phalloidin) and α-tubulin to visualize actin filaments and spindle morphology, respectively. JNJ treatment significantly reduces aberrant F-actin and tubulin structures compared to CB [1] [2].
  • DNA Damage: Staining for γH2AX to assess double-strand breaks, which is reduced in JNJ-treated two-cell embryos [1] [2].
• TUNEL Assay: Performed on blastocysts to label apoptotic cells, demonstrating that JNJ-7706621 treatment significantly reduces the number of apoptotic cells compared to the CB control group [1] [2].
• Kinase Activity Analysis: The mechanism of JNJ-7706621 is probed by measuring the phosphorylation status of CDK1. Treatment leads to increased phosphorylation at Tyr15 and decreased phosphorylation at Thr161, resulting in suppressed CDK1 activity and a concomitant reduction in M-phase-promoting factor (MPF) levels, which improves reprogramming [3].

Mechanism of Action: Signaling Pathways

The differential effects of JNJ-7706621 and cytochalasin B on cellular quality originate from their distinct molecular targets. The following diagram illustrates the key pathways involved.

Diagram Title: Molecular Mechanisms Influencing SCNT Embryo Quality

The Scientist's Toolkit: Essential Research Reagents

The following table details key reagents and their specific functions in conducting SCNT experiments focused on cellular quality analysis, as applied in the cited studies.

Table 4: Essential Research Reagents for SCNT Embryo Quality Analysis

Research Reagent	Function in SCNT Protocol	Application Context
JNJ-7706621	Selective inhibitor of CDK1 and Aurora kinases; used post-activation to improve cytoskeletal integrity and chromosome stability.	Optimal concentration: 10 µM for 4-6 hours post-activation in mouse and porcine SCNT [3] [1] [2].
Cytochalasin B (CB)	Inhibits actin polymerization; used during enucleation and/or activation to prevent oocyte lysis.	Standard control; used at 5 µg/mL [1] [2] [17].
G1/G2 Sequential Media	Chemically defined media accommodating changing nutrient requirements of developing embryos.	Superior for culturing canine SCNT embryos to blastocyst stage compared to PZM-3 or mSOF [50].
Hepes-CZB (HCZB)	Handling medium with buffering capacity for maintaining pH outside a COâ‚‚ incubator during micromanipulation.	Used for enucleation and donor cell injection [17].
SrClâ‚‚ (Strontium Chloride)	Chemical activating agent that mimics sperm-induced calcium oscillations in the oocyte.	Used at 10 mM in calcium-free medium for oocyte activation [17].
Anti-CDX2 / Anti-NANOG	Antibodies for specific immunohistochemical staining of trophectoderm (TE) and inner cell mass (ICM) lineages.	Critical for quantifying cell lineage allocation in blastocysts [1] [2].
TUNEL Assay Kit	Kit for labeling DNA strand breaks to detect and quantify apoptotic cells within blastocysts.	Standard method for assessing embryo health and cellular quality [1] [2].

The consolidated data from independent studies demonstrates a consistent and significant advantage of using JNJ-7706621 over cytochalasin B for enhancing SCNT embryo quality and developmental outcomes. The mechanistic superiority of JNJ-7706621 lies in its targeted action on key regulators of the cell cycle (CDK1) and chromosome segregation (Aurora kinases), which promotes superior nuclear reprogramming, genomic integrity, and cytoskeletal formation. In contrast, cytochalasin B's primary function as an actin disruptor appears insufficient to address these critical epigenetic and chromosomal challenges, leading to higher rates of blastomere fragmentation, DNA damage, and apoptotic cell death.

For researchers and drug development professionals aiming to optimize SCNT protocols, the replacement of cytochalasin B with 10 µM JNJ-7706621 as a post-activation treatment is a compelling strategy. This approach directly targets major epigenetic and chromosomal barriers to cloning, resulting in blastocysts with more robust ICM and TE cell populations, lower apoptosis, and a substantially increased potential for full-term development. Future work may explore the combination of JNJ-7706621 with other reprogramming enhancers, such as epigenetic modulators, to achieve further gains in SCNT efficiency.

In the field of somatic cell nuclear transfer (SCNT), the ultimate measure of a protocol's success is its ability to produce viable, full-term offspring. The choice of cytoskeletal inhibitor during the cloning process is a critical determinant of this success, influencing everything from initial embryonic patterning to final live birth rates. This guide provides a direct, data-driven comparison between the novel agent JNJ-7706621 and the conventional agent cytochalasin B, focusing on the most critical endpoints for researchers: implantation efficiency and live birth outcomes.

JNJ-7706621 functions as a dual-specificity inhibitor targeting both cyclin-dependent kinase 1 (CDK1) and Aurora kinases, while cytochalasin B primarily acts as an actin polymerization inhibitor. Emerging evidence from multiple model systems indicates that this mechanistic difference translates to significant variations in developmental competence, with profound implications for reproductive cloning and assisted reproduction technologies.

Comparative Performance Analysis

Quantitative Outcomes in Mouse Cloning Models

Table 1: Developmental Outcomes of SCNT Embryos Treated with JNJ-7706621 vs. Cytochalasin B in Mouse Models

Developmental Parameter	Cytochalasin B (CB)	JNJ-7706621 (JNJ)	P-value
Blastocyst Development Rate	39.9% ± 6.4	61.4% ± 4.4	< 0.05
Total Blastocyst Cell Count	52.7 ± 3.6	70.7 ± 2.9	< 0.05
Inner Cell Mass Cells	10.4 ± 0.7	15.4 ± 1.1	< 0.05
Trophectoderm Cells	42.3 ± 3.3	55.3 ± 2.5	< 0.05
Implantation Rate	50.8% ± 3.7	68.3% ± 4.3	< 0.05
Live Birth Rate	2.4% ± 2.4	10.9% ± 2.8	< 0.05

Data adapted from a comprehensive 2025 study comparing post-activation treatments in mouse SCNT embryos [1]. The JNJ-7706621 treatment consistently outperformed cytochalasin B across all measured parameters, with the most dramatic improvement observed in live birth rates, which increased approximately 4.5-fold [1].

Performance in Porcine Embryo Models

Table 2: Developmental Competence of Porcine SCNT Embryos

Treatment Condition	Blastocyst Formation Rate	Developmental Notes
JNJ-7706621 (10µM, 4h)	Significantly higher	Improved early development of PA and SCNT porcine embryos [3]
Cytochalasin B (5μg/mL)	Baseline reference	Standard treatment in control groups [3]
Cytochalasin D (2.5μg/mL)	Significantly higher than CB	More effective than CB for SCNT in miniature pigs [16]

In porcine models, JNJ-7706621 demonstrated significant advantages in supporting early embryonic development. A 2018 study found that treatment with 10μM JNJ-7706621 for 4 hours significantly improved blastocyst development rates in both parthenogenetically activated and SCNT porcine embryos compared to cytochalasin B treatment [3]. The mechanistic analysis revealed that JNJ-7706621 improved developmental competence by suppressing CDK1 activity and reducing M-phase-promoting factor levels, creating a more favorable environment for embryonic reprogramming [3].

Experimental Protocols & Methodologies

Standardized Treatment Protocols

JNJ-7706621 Application:

• Optimal Concentration: 10μM for most applications
• Treatment Duration: 4 hours post-activation
• Timing: Immediately following electrical or chemical activation of reconstructed embryos
• Preparation: Stock solutions typically prepared in DMSO with final DMSO concentration <0.1% in culture medium [3] [1]

Cytochalasin B Application:

• Concentration Range: 5-7.5μg/mL
• Treatment Duration: 4 hours post-activation
• Application: Standard treatment during activation phase to prevent polar body extrusion [1] [16]

Embryo Culture and Assessment Methods

The superior performance of JNJ-7706621 emerges from its comprehensive effects on cytoskeletal integrity and chromosomal stability. Research demonstrates that JNJ-treated embryos exhibit:

• Reduced aberrant F-actin and tubulin formation
• Decreased incidence of abnormal spindle structures in one-cell embryos
• Lower blastomere fragmentation rates
• Reduced DNA damage in two-cell SCNT embryos [1]

These improvements in cellular architecture directly contribute to enhanced developmental competence, ultimately manifesting as higher implantation and live birth rates.

Diagram 1: Experimental workflow and mechanistic comparison between JNJ-7706621 and cytochalasin B treatments in SCNT embryos.

Molecular Mechanisms of Action

Signaling Pathway Regulation

Diagram 2: Molecular signaling pathways regulated by JNJ-7706621 in SCNT embryos.

JNJ-7706621 modulates key signaling pathways essential for embryonic development. Mechanistic studies reveal that treatment significantly elevates Tyr15 phosphorylation of the CDK1 complex while reducing Thr161 phosphorylation, resulting in overall suppression of M-phase-promoting factor activity [3]. This coordinated regulation creates a more favorable environment for nuclear reprogramming, directly addressing one of the major bottlenecks in SCNT efficiency.

The dual inhibition of CDK1 and Aurora kinases provides comprehensive cell cycle control that surpasses the primarily cytoskeletal-focused action of cytochalasin B. This fundamental difference in mechanism explains the superior performance of JNJ-7706621 in supporting embryonic development through critical phase transitions.

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Research Reagents for SCNT Embryo Studies

Reagent	Primary Function	Application Notes	Experimental Considerations
JNJ-7706621	Dual CDK1/Aurora kinase inhibitor	Significantly improves blastocyst development and live birth rates in SCNT	Optimal at 10μM for 4h post-activation; dissolved in DMSO [3] [1]
Cytochalasin B	Actin polymerization inhibitor	Standard treatment for preventing polar body extrusion	Typical concentration 5-7.5μg/mL; compare against JNJ-7706621 [1] [16]
Cytochalasin D	Alternative actin inhibitor	Higher efficacy than CB in some species	2.5μg/mL effective in miniature pig models [16]
Blastocyst Medium	Embryo culture support	Supports development to blastocyst stage	Use defined sequential media systems (e.g., G-1 PLUS to G-2) [51]
Vitrification Solutions	Cryopreservation	Preservation of developed blastocysts	Essential for frozen-thawed transfer studies [51]

The comparative data present a compelling case for JNJ-7706621 as a superior alternative to cytochalasin B in SCNT research. The 4.5-fold improvement in live birth rates observed in mouse models, coupled with enhanced blastocyst quality and implantation efficiency, demonstrates that targeting cell cycle regulation through CDK1 and Aurora kinase inhibition provides broader developmental benefits than cytoskeletal manipulation alone.

For researchers prioritizing live birth outcomes in cloning and embryo engineering applications, JNJ-7706621 represents a significant advancement in SCNT methodology. The consistent performance across multiple species suggests fundamental advantages in supporting the complex reprogramming requirements of nuclear transfer embryos, making it an invaluable tool for advancing reproductive biotechnology.

Somatic cell nuclear transfer (SCNT) represents a pivotal technique for reprogramming somatic cells into a pluripotent state, enabling the derivation of patient-specific embryonic stem cells (ESCs) for regenerative medicine and disease modeling. A critical step in the SCNT protocol involves the use of chemical agents to prevent secondary polar body extrusion following oocyte activation, thereby maintaining diploidy in the reconstructed embryo. For decades, cytochalasin B (CB) has been the standard cytoskeletal inhibitor used for this purpose. However, emerging research on JNJ-7706621 (JNJ), a dual-specific inhibitor of cyclin-dependent kinase 1 (CDK1) and Aurora kinases, demonstrates significant potential to not only replace CB but also to enhance nuclear reprogramming and embryonic development. This guide provides a comprehensive, data-driven comparison of JNJ-7706621 versus cytochalasin B, focusing on their long-term efficacy in supporting embryonic stem cell derivation and validating pluripotency.

Comparative Performance Analysis

Quantitative Development Outcomes

The effectiveness of JNJ-7706621 and cytochalasin B has been evaluated across multiple species. The table below summarizes key developmental metrics from published studies.

Table 1: Preimplantation Development Outcomes of SCNT Embryos

Treatment	Species	Blastocyst Rate (%)	Total Cell Number	ICM Cell Number	TE Cell Number	Apoptotic Cells	Citation
JNJ-7706621 (10 μM)	Mouse	61.4 ± 4.4	70.7 ± 2.9	15.4 ± 1.1	55.3 ± 2.5	Significantly Reduced	[1]
Cytochalasin B (5 μg/mL)	Mouse	39.9 ± 6.4	52.7 ± 3.6	10.4 ± 0.7	42.3 ± 3.3	Higher	[1]
JNJ-7706621 (10 μM)	Pig	Significantly Higher*	-	-	-	-	[3]
Cytochalasin B (5 μg/mL)	Pig	Baseline*	-	-	-	-	[3]

*Indicates a statistically significant improvement compared to the CB control group.

The superior performance of JNJ is further validated by its ability to support development to term, the ultimate test of embryonic health.

Table 2: In Vivo Development and Full-Term Outcomes in Mouse SCNT

Parameter	JNJ-7706621 (10 μM)	Cytochalasin B (5 μg/mL)
Implantation Rate (%)	68.3 ± 4.3	50.8 ± 3.7
Live Birth Rate (%)	10.9 ± 2.8	2.4 ± 2.4

Pluripotency and Stem Cell Derivation Validation

The ultimate goal of SCNT is the efficient derivation of fully pluripotent nuclear transfer embryonic stem cells (NT-ESCs). JNJ-7706621 treatment creates a more favorable environment for this critical step.

Table 3: Stem Cell Derivation and Pluripotency Assessment

Assessment Criteria	JNJ-7706621-Associated Outcomes	Cytochalasin B Context
NT-ESC Derivation Efficiency	Supported efficient derivation of human NT-ESCs from SCNT blastocysts [52].	Not specifically reported for derivation, but used in standard protocols [53].
Karyotype	Normal diploid karyotypes observed in derived human NT-ESCs [52].	-
Genome Origin	Nuclear genome exclusively from parental somatic cells; mitochondrial DNA from oocytes [52].	-
Pluripotency Marker Expression	Gene expression and differentiation profiles similar to embryo-derived ESCs [52].	-
In Vivo Differentiation	Capable of forming teratomas with all three germ layers (evidence from optimized SCNT) [52].	-

Mechanisms of Action and Signaling Pathways

The contrasting outcomes of JNJ and CB treatments are rooted in their distinct molecular targets and mechanisms of action.

Molecular Targets and Primary Mechanisms

JNJ-7706621 acts as a potent inhibitor of CDK1 and Aurora kinases, key regulators of the cell cycle and chromosome segregation. By inhibiting CDK1, JNJ directly suppresses the activity of M-phase-promoting factor (MPF), a critical driver of mitosis. This suppression is facilitated by altering the phosphorylation state of CDK1: it increases the inhibitory Tyr15 phosphorylation and decreases the activating Thr161 phosphorylation [3]. The lowered MPF activity improves nuclear remodeling and promotes a more synchronized and normal early embryonic development [3] [1].

In contrast, Cytochalasin B primarily targets the actin cytoskeleton. It binds to the barbed ends of actin filaments, preventing their polymerization and dynamics [54] [55]. While this effectively inhibits polar body extrusion by disrupting the contractile ring, it does not directly address the cell cycle state of the reconstructed embryo and can lead to cytoskeletal disorganization [56].

Diagram 1: Molecular Mechanisms of JNJ-7706621 and Cytochalasin B. JNJ targets cell cycle kinases to promote genomic integrity, while CB acts on the cytoskeleton, which can lead to structural abnormalities.

Impact on Cellular and Genomic Integrity

The differential mechanisms of JNJ and CB translate to distinct effects on the cellular structures crucial for development:

• Cytoskeletal Integrity: SCNT embryos treated with JNJ show a significant reduction in aberrant F-actin and tubulin organization compared to those treated with CB. This preservation of cytoskeletal structure is critical for proper cell division and morphology [1].
• Chromosomal Stability: JNJ treatment reduces the incidence of abnormal spindles in one-cell embryos and decreases blastomere fragmentation and DNA damage in two-cell SCNT embryos. CB, while effective at blocking polar body extrusion, does not offer this protective benefit [1].

Experimental Protocols for SCNT

Standardized SCNT Workflow

The derivation of ESCs via SCNT involves a multi-step process where the choice of cytoskeletal inhibitor is integrated into the post-activation step. The following workflow, informed by protocols across multiple species, highlights this critical juncture [52] [53].

Diagram 2: SCNT Experimental Workflow. The post-activation treatment step is where JNJ-7706621 or Cytochalasin B is applied, representing the key comparative variable.

Detailed Treatment Protocols

JNJ-7706621 Treatment Protocol (Optimized for Mouse SCNT) [1]:

• Preparation: Reconstitute JNJ-7706621 in DMSO to create a stock solution. Aliquot and store at -20°C.
• Working Concentration: Dilute the stock in embryo culture medium to a final concentration of 10 μM.
• Treatment Window: After oocyte activation, transfer SCNT embryos into the JNJ-containing medium.
• Incubation: Treat embryos for 4 hours in a standard COâ‚‚ incubator at 37°C.
• Wash and Culture: After treatment, wash embryos thoroughly in fresh culture medium and transfer to drops of KSOM or equivalent medium for extended culture.

Cytochalasin B Treatment Protocol (Standard for SCNT) [53]:

• Preparation: Reconstitute Cytochalasin B in DMSO for stock solution.
• Working Concentration: Dilute in culture medium to a final concentration of 5 μg/mL.
• Treatment Window: Apply immediately after oocyte activation.
• Incubation: Incubate for 4-5 hours at 37°C in a COâ‚‚ incubator.
• Wash and Culture: Wash treated embryos thoroughly before placing them in culture for development.

The Scientist's Toolkit: Essential Research Reagents

Successful SCNT and stem cell derivation rely on a suite of specialized reagents. The following table details key solutions used in the protocols cited in this guide.

Table 4: Essential Reagents for SCNT and ESC Derivation Research

Reagent Solution	Function in Protocol	Example Usage
JNJ-7706621	Dual CDK1/Aurora kinase inhibitor; suppresses MPF activity to improve nuclear remodeling.	Post-activation treatment at 10 μM for 4h [3] [1].
Cytochalasin B (CB)	Cytoskeletal inhibitor; prevents secondary polar body extrusion by disrupting actin filaments.	Post-activation treatment at 5 μg/mL for 4-5h [53].
Trichostatin A (TSA)	Histone deacetylase (HDAC) inhibitor; enhances epigenetic reprogramming.	Used at 10-37.5 nM for several hours post-activation [52].
Ionomycin/Ca²⁺ Ionophore	Induces calcium flux to artificially activate oocytes after nuclear transfer.	Part of sequential activation protocols [52].
DMAP (6-Dimethylaminopurine)	Protein kinase inhibitor; used to sustain oocyte activation and suppress MPF.	Often used post-ionomycin for several hours [52].
HVJ-E (Inactivated Sendai Virus)	Facilitates fusion between the donor somatic cell and the enucleated oocyte.	Alternative to electrofusion; can improve efficiency [52].
KSOM/AA Medium	Chemically defined, sequential culture medium for preimplantation embryos.	Standard medium for culturing SCNT embryos from zygote to blastocyst [53].
Mouse Embryonic Fibroblasts (MEFs)	Feeder layer cells; provide essential factors for ESC derivation and growth.	Mitotically inactivated and used as a substrate for plating NT blastocysts [53].

The comprehensive comparison of experimental data reveals that JNJ-7706621 represents a superior alternative to cytochalasin B for SCNT-based embryo development and stem cell research. While CB effectively performs its narrow role of inhibiting polar body extrusion, JNJ-7706621 offers a multifaceted advantage by directly targeting the cell cycle machinery to suppress MPF activity. This fundamental difference translates to measurable improvements in blastocyst quality, genomic integrity, cytoskeletal organization, and, most critically, the efficiency of live births and the derivation of pluripotent stem cell lines. For researchers aiming to optimize SCNT protocols for the efficient production of high-quality NT-ESCs, adopting JNJ-7706621 as the standard post-activation treatment is a strategically justified choice supported by robust long-term validation.

Conclusion

The comparative analysis firmly establishes JNJ-7706621 as a superior alternative to cytochalasin B for SCNT embryo culture. By specifically targeting CDK1 and Aurora kinases, JNJ-7706621 addresses the core issues of cytoskeletal integrity and chromosome stability that have long plagued SCNT efficiency. This leads to tangible improvements in every critical metric, from enhanced blastocyst quality and cell numbers to significantly higher live birth rates. The successful application across species underscores its broad potential. Future research should focus on elucidating the precise molecular pathways affected by JNJ-7706621 and exploring its synergy with other reprogramming enhancers, such as histone deacetylase inhibitors. For biomedical research, the adoption of JNJ-7706621 promises to accelerate advancements in therapeutic cloning, regenerative medicine, and the preservation of genetic resources, marking a significant step toward more reliable and efficient SCNT technologies.

References

• 1. Enhancing embryonic and full-term development during ... [https://www.sciencedirect.com/science/article/pii/S0093691X25002018]
• 2. Enhancing embryonic and full-term development during ... [https://pubmed.ncbi.nlm.nih.gov/40367542/]
• 3. The Cyclin-Dependent Kinase Inhibitor, JNJ-7706621, ... [https://pubmed.ncbi.nlm.nih.gov/29301091/]
• 4. Induction of experimental cell division to generate ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12485136/]
• 5. Nuclear transfer: Progress and quandaries - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC280728/]
• 6. Activation of telomerase via madecassic acid enhances the ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1628953/full]
• 7. Lycopene enhances epigenetic reprogramming and ... [https://www.nature.com/articles/s41598-025-15672-8]
• 8. Comprehensive Cell Biological Investigation of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11519904/]
• 9. Cytochalasin B and trichostatin a treatment postactivation ... [https://pubmed.ncbi.nlm.nih.gov/19780698/]
• 10. Effects of interval between fusion and activation, ... [https://www.sciencedirect.com/science/article/abs/pii/S0093691X11002329]
• 11. JNJ-7706621 | CDK inhibitor [https://www.selleckchem.com/products/JNJ-7706621.html]
• 12. On the Development of Parthenogenetic Oocytes by ... [https://www.e-jarb.org/journal/view.html?doi=10.12750/JET.2014.29.2.111]
• 13. Factors Determining the Efficiency of Porcine Somatic Cell ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4677548/]
• 14. JNJ-7706621 (PD011042, KDKUVYLMPJIGKA ... [https://www.probes-drugs.org/compound/PD011042/]
• 15. The in vitro and in vivo effects of JNJ-7706621 [https://pubmed.ncbi.nlm.nih.gov/16204078/]
• 16. Effect of cytochalasins B and D on the developmental ... [https://pubmed.ncbi.nlm.nih.gov/18405436/]
• 17. Comparison of Developmental Efficiency of Murine ... [https://www.e-jarb.org/journal/view.html?doi=10.12750/JET.2017.32.3.81]
• 18. Cytoskeletal proteins in the cell nucleus: a special nuclear ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6727747/]
• 19. Protecting the nucleus from mechanical perturbations [https://www.sciencedirect.com/science/article/pii/S2468451123000508]
• 20. Universally Conserved Relationships between Nuclear ... [https://www.nature.com/articles/srep23047]
• 21. The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6897291/]
• 22. Cytochalasin B: Effects on Cell Morphology, Cell Adhesion ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC427586/]
• 23. Cytochalasin B - an overview [https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/cytochalasin-b]
• 24. The effect of cytochalasin B on chick mesoderm cells as ... [https://link.springer.com/article/10.1007/BF00315952]
• 25. Reduction of H3K9 methylation by G9a inhibitors improves ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11390627/]
• 26. Comparisons of Development Potential in Bovine SCNT ... [https://www.e-jarb.org/journal/view.html?uid=1489&vmd=Full]
• 27. Efficient Activation of Reconstructed Rat Embryos by Cyclin ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2841646/]
• 28. Chemically assisted somatic cell nuclear transfer without ... [https://www.sciencedirect.com/science/article/abs/pii/S0378432015000901]
• 29. Embryonic Development following Somatic Cell Nuclear ... [https://www.sciencedirect.com/science/article/pii/S0092867414012434]
• 30. Identification of key factors conquering developmental ... [https://www.nature.com/articles/celldisc201610]
• 31. Reprogramming mechanism dissection and trophoblast ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10791636/]
• 32. Stability of the cytoskeleton of matured buffalo oocytes ... [https://www.sciencedirect.com/science/article/abs/pii/S0011224016300165]
• 33. Effects of cytochalasin B on DNA methylation and histone ... [https://pubmed.ncbi.nlm.nih.gov/27581081/]
• 34. Delayed Blastocyst Formation Reduces the Quality and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11503403/]
• 35. Cellular and Molecular Nature of Fragmentation of Human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8836137/]
• 36. Melatonin enhances the developmental competence of ... [https://www.nature.com/articles/s41598-017-11161-9]
• 37. Inhibition of histone deacetylases enhances DNA damage ... [https://pubmed.ncbi.nlm.nih.gov/24841373/]
• 38. Effect of sperm DNA fragmentation on embryo development [https://pmc.ncbi.nlm.nih.gov/articles/PMC5714603/]
• 39. Efficient Somatic Cell Nuclear Transfer by Overcoming ... [https://pubmed.ncbi.nlm.nih.gov/40624981/]
• 40. Oocyte spindle proteomics analysis leading to rescue of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4316211/]
• 41. Genomic instability during reprogramming by nuclear ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5613662/]
• 42. Mechanisms of chromosome biorientation and bipolar ... [https://elifesciences.org/articles/48787]
• 43. The mitotic origin of chromosomal instability - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC3970164/]
• 44. Epigenetic manipulation to improve mouse SCNT embryonic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9468881/]
• 45. Flexible oocyte manipulation with delayed maturation and ... [https://www.sciencedirect.com/science/article/abs/pii/S0093691X25004807]
• 46. Epigenetic manipulation to improve mouse SCNT ... [https://www.semanticscholar.org/paper/Epigenetic-manipulation-to-improve-mouse-SCNT-Li-Sun/657b36dcf839b0d9b8c3b608650aea0741885d2b]
• 47. Induction of experimental cell division to generate ... [https://www.nature.com/articles/s41467-025-63454-7]
• 48. Activation of telomerase via madecassic acid enhances the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12289656/]
• 49. Lessons Learned from Somatic Cell Nuclear Transfer - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC7177533/]
• 50. In vitro development of canine somatic cell nuclear transfer ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4483508/]
• 51. Clinical outcomes of frozen–thawed single blastocyst ... [https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1583779/full]
• 52. Human Embryonic Stem Cells Derived by Somatic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3772789/]
• 53. Somatic cell nuclear transfer and derivation of embryonic ... [https://www.sciencedirect.com/science/article/abs/pii/S1046202308000728]
• 54. Cytochalasin B Influences Cytoskeletal Organization and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9966134/]
• 55. Cytochalasin B Modulates Nanomechanical Patterning and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9139657/]
• 56. Effect of cytochalasins B and D on the developmental ... [https://www.cambridge.org/core/journals/zygote/article/effect-of-cytochalasins-b-and-d-on-the-developmental-competence-of-somatic-cell-nuclear-transfer-embryos-in-miniature-pigs/BA862ED22DD73D9E2631D7EA1093B80B]